{
  "metadata": {
    "total_articles_classified": 512,
    "good_candidates": 242,
    "bad_candidates": 270,
    "classification_timestamp": "2025-10-22 23:26:22",
    "classifier": "Gemini AI"
  },
  "classifications": [
    {
      "pmid": "35378172",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study utilizing murine (mouse) models exclusively.",
        "Focuses on mechanistic outcomes (T-cell function, transcriptomic analysis) rather than human clinical endpoints (OS, PFS)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37195082",
      "is_good_candidate": false,
      "reasons": [
        "Mechanistic study relying on single-cell RNA sequencing and metabolic analysis.",
        "Lacks robust, defined human clinical trial data or large observational cohort data."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "37147018",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study using in vitro models (murine and human CD8 T cells) and in vivo mouse models.",
        "Outcomes are mechanistic (apoptosis, proliferation, cytokine production), not clinical efficacy endpoints."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36108523",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is empty; insufficient information to determine study design, methodology, or outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35852878",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is empty; insufficient information to determine study design, methodology, or outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34246699",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is empty; insufficient information to determine study design, methodology, or outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36012397",
      "is_good_candidate": false,
      "reasons": [
        "Animal study using tumor-bearing mice (Lewis Lung Carcinoma xenograft models).",
        "Outcomes are preclinical (tumor growth, circulating molecular levels) in mice."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39560490",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective analysis of two clinical cohorts (human NSCLC patients) with clear clinical outcomes (RFS, PFS, OS).",
        "Utilizes defined statistical methods (Hazard Ratio, Confidence Interval) suitable for meta-analysis."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "37582751",
      "is_good_candidate": false,
      "reasons": [
        "Mechanistic study focused on drug resistance pathways (SE-TFs-PTGR1 axis) in PCa cells.",
        "Lacks large-scale human clinical trial data or definitive clinical efficacy outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35724834",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is empty; insufficient information to determine study design, methodology, or outcomes. Title suggests a mechanistic focus."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36857596",
      "is_good_candidate": true,
      "reasons": [
        "Analysis of a large, well-defined human cohort (ASPREE trial participants) with diabetes (N=2045).",
        "Uses rigorous statistical methods (Cox proportional hazards regression) and reports quantifiable clinical outcomes (cancer incidence, mortality) with HRs and CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35714813",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is empty; insufficient information to determine study design, methodology, or outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37409755",
      "is_good_candidate": false,
      "reasons": [
        "Primarily an in vitro study using cell lines and xenograft models.",
        "Focus is on molecular mechanism (ER stress-CHOP pathway) and synergy, not powered clinical outcomes."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "40091020",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study using TNBC cell lines and nude mouse xenograft models.",
        "Outcomes are cellular assays and tumor growth inhibition in mice, lacking human clinical data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27356748",
      "is_good_candidate": false,
      "reasons": [
        "Review article/Commentary discussing the rationale and challenges of repurposing metformin for cancer.",
        "Does not present original primary research data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37213670",
      "is_good_candidate": false,
      "reasons": [
        "In vitro study investigating human gastric cancer cell lines (AGS cells).",
        "Outcomes are cellular/molecular (growth inhibition, apoptosis), not clinical efficacy."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39630677",
      "is_good_candidate": true,
      "reasons": [
        "Large human observational study (retrospective case-control) using a large database ('All of Us').",
        "Utilizes rigorous methodology (propensity score matching and multivariable regression) to control for confounders.",
        "Reports clear clinical outcome (cancer risk) with statistical metrics (ORs)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "33191721",
      "is_good_candidate": false,
      "reasons": [
        "In vitro study using various cancer cell lines.",
        "Outcomes are based on viability and proliferation measurements (MTT assay), not human clinical data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37030634",
      "is_good_candidate": false,
      "reasons": [
        "Animal study using a murine model (KC mice) of pancreatic carcinogenesis.",
        "Outcomes are preclinical, focused on molecular mechanism (NETs, inflammation) and mPanIN progression in mice."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37225730",
      "is_good_candidate": true,
      "reasons": [
        "Human observational cohort study with an adequate sample size (N=492) of early-stage CRC patients.",
        "Clear clinical outcomes reported (RFS and OS) analyzed using multivariate modeling, including HRs and p-values."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39541840",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical/mechanistic study focused on nanoparticle design (Fe-PDA-MET NP) and molecular pathways (ferroptosis, TIME remodeling).",
        "Lacks large-scale human clinical trial data on efficacy."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "36726289",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study focusing on physiological mechanism (salivary function/AMPK pathway) following radiation.",
        "Likely uses animal or cell models, lacking human cancer treatment outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34052334",
      "is_good_candidate": false,
      "reasons": [
        "Designated as a 'Reply' (letter or editorial comment).",
        "Does not present original primary research data for inclusion."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40520024",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study using a mouse model (PCOS-like mice) and in vitro cell models.",
        "Focuses on molecular mechanisms (Ethe1/Keap1/PINK1 pathway) and metabolic markers in animals."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40105683",
      "is_good_candidate": true,
      "reasons": [
        "Phase II randomized controlled trial (RCT) in human patients (N=41).",
        "Clear population and intervention (metformin + CRT vs. CRT). Provides human safety and feasibility data, and while preliminary, is a controlled trial design."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "35078642",
      "is_good_candidate": true,
      "reasons": [
        "Observational cohort study (N=1064 patients) with prospective follow-up for HCC.",
        "Reports definitive clinical outcomes (HCC incidence and OS) using Cox proportional hazards analysis (HRs and P-values)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38530777",
      "is_good_candidate": true,
      "reasons": [
        "Observational study leveraging a cohort derived from a randomized controlled trial (PREOPANC RCT).",
        "Reports robust clinical outcomes (Overall Survival) in pancreatic cancer patients with statistical metrics (HR=0.56; 95% CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "23358989",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is empty; insufficient information to determine study design, methodology, or outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35831458",
      "is_good_candidate": true,
      "reasons": [
        "Large human observational cohort study (N=41,533).",
        "High methodological rigor, specifically employing three methods (time-dependent Cox, landmark, nested case-control) to avoid immortal time bias.",
        "Reports clear outcome (CRC incidence) with HRs and CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "31491730",
      "is_good_candidate": true,
      "reasons": [
        "Large national cohort study (N=15,052) of colorectal cancer patients.",
        "Reports definitive clinical outcomes (Cancer-Specific Survival and Overall Survival) using Cox regression (HRs and CIs)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25076330",
      "is_good_candidate": false,
      "reasons": [
        "Review article summarizing epidemiological data and conference abstracts.",
        "Does not present original primary research data suitable for quantitative synthesis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39933530",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study using TNBC cell lines and patient-derived xenograft models (mice).",
        "Focuses on molecular pathways (c-Src, mitochondrial reprogramming) and synergy in mice, lacking human clinical outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39893002",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study utilizing CRPC cell lines and xenograft models (in vitro and in vivo).",
        "Focus is on resistance mechanisms and mitochondrial fitness, not human clinical efficacy."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36328378",
      "is_good_candidate": false,
      "reasons": [
        "Primarily a mechanistic study focusing on immunological outcomes (NK cell function, cytokine expression) and molecular pathways (CXCL1).",
        "Relies on Phase I trials, which are preliminary and designed for safety/dosing, not powered for efficacy meta-analysis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "39923680",
      "is_good_candidate": true,
      "reasons": [
        "Phase II randomized, placebo-controlled trial (RCT) in human patients (N=108).",
        "Reports clear clinical efficacy outcomes (PFS and OS) with statistical measures (HR, CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36321555",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study using HCC cell lines and in vitro/in vivo models.",
        "Focuses on metabolic adaptation and molecular targets (TOMM34/ATP5B axis), lacking human clinical data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30022336",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective human cohort study of veterans (N=84,434).",
        "High methodological rigor, including propensity score matching and Cox regression, specifically addressing time-related biases.",
        "Reports clear clinical outcomes (incidence cancer risk) with robust statistics (aHR, CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40434511",
      "is_good_candidate": false,
      "reasons": [
        "Phase Ib dose-finding and pharmacokinetic (PK) trial (N=41).",
        "Primary goals are safety and dose escalation (MTD/PK). Efficacy outcomes (PFS/OS) are highly preliminary and often underpowered for inclusion in meta-analyses seeking definitive treatment effects."
      ],
      "confidence_score": 0.85
    },
    {
      "pmid": "30046513",
      "is_good_candidate": false,
      "reasons": [
        "In vitro study using Glioblastoma multiforme (GBM) cell lines.",
        "Outcomes are cellular/molecular metrics (motility, invasion, AKT inactivation), not human clinical data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40090535",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study using a rat PCOS model (animal study).",
        "Outcomes are based on animal phenotypic, hormonal, and genotypic determinants, not human clinical efficacy."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37047828",
      "is_good_candidate": false,
      "reasons": [
        "Pilot intervention study with a very small sample size (N=8 PCOS patients).",
        "Primary outcomes are molecular biomarkers (DNA methylation and gene expression), not powered clinical endpoints."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35780231",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study using cancer cell lines and xenograft mouse models.",
        "Outcomes are based on cellular assays and liver metastatic rate in mice, lacking human clinical efficacy data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29274360",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study using nude mice xenograft models (animal study).",
        "Outcomes focus on tumor growth inhibition in mice and molecular mechanisms (autophagy), not human clinical data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39160673",
      "is_good_candidate": false,
      "reasons": [
        "Primarily a mechanistic study focusing on in vitro cell biology (radiosensitization, ROS levels) and molecular targets (GAPDH and TAGLN2).",
        "Lacks robust clinical efficacy data (PFS, OS) from a controlled human trial."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "28185288",
      "is_good_candidate": false,
      "reasons": [
        "Window of opportunity trial (Phase 0/I) with a small sample size (N=39 completed).",
        "Primary endpoints are pharmacodynamic and biomarker changes (CAV1, GALB, apoptosis) rather than clinical efficacy/survival outcomes required for meta-analysis of treatment effect."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "22689798",
      "is_good_candidate": true,
      "reasons": [
        "Large prospective human cohort study derived from Women's Health Initiative clinical trials (N=68,019).",
        "Reports clear clinical outcome (invasive breast cancer incidence) using robust statistical methods (Cox regression, HRs, CIs)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39463147",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical/mechanistic study using HNSCC cell systems (in vitro and in vivo models).",
        "Focuses on genetic resistance mechanisms (HRAS mutation) and metabolic pathways, lacking human clinical efficacy data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38167322",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study using an experimental carcinoma model in syngeneic mice (animal study).",
        "Outcomes are preclinical (tumor growth inhibition in mice, Granzyme B expression), lacking human clinical data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "24496803",
      "is_good_candidate": true,
      "reasons": [
        "Large human cohort study (N=87,600) using a major database.",
        "Employs rigorous methods (time-dependent variable analysis, Cox regression) specifically to avoid time-related biases common in observational studies.",
        "Reports clear clinical outcome (bladder cancer incidence) with HRs and CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34165313",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study focusing on drug delivery system design (microspheres) and formulation efficacy.",
        "Outcomes are based on inhibition of metastasis in preclinical models (*in vivo* testing), lacking human clinical data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40179096",
      "is_good_candidate": true,
      "reasons": [
        "Robust Mendelian randomization (MR) methodology, suitable for inferring causality in meta-analysis.",
        "Utilizes strong statistical methods (IVW, MR-Egger, sensitivity analyses).",
        "Analysis is based on human genetic data from GWAS."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "22497968",
      "is_good_candidate": false,
      "reasons": [
        "Abstract content is missing.",
        "Cannot assess study methodology, population, or outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39689458",
      "is_good_candidate": false,
      "reasons": [
        "Primarily an in vitro (cellular assays) and preclinical mechanism study.",
        "Uses a xenograft mouse model (animal study).",
        "Lacks human clinical trial data or large-scale epidemiological outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36224510",
      "is_good_candidate": false,
      "reasons": [
        "Abstract content is missing.",
        "Cannot assess study methodology, population, or outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38807407",
      "is_good_candidate": false,
      "reasons": [
        "Appears to be a commentary, hypothesis, or discussion focusing on rare clinical observations (case reports).",
        "Lacks rigorous epidemiological study methodology (RCT or large cohort) necessary for quantitative synthesis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "35140015",
      "is_good_candidate": true,
      "reasons": [
        "Large observational cohort study (N=6225).",
        "Clear clinical outcome (survival).",
        "Uses robust statistical methods including Cox proportional hazards models and nested case-control matching with reported HRs and 95% CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34720054",
      "is_good_candidate": false,
      "reasons": [
        "In vitro/laboratory mechanism study using cancer cell lines.",
        "Preclinical investigation lacking human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "26490666",
      "is_good_candidate": false,
      "reasons": [
        "Animal study (cancer-bearing cats).",
        "Pilot study design (N=9), focusing on toxicity and biomarkers.",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25843797",
      "is_good_candidate": false,
      "reasons": [
        "In vitro/cellular mechanism study using human liver cancer cells.",
        "Focuses on molecular pathways (mTOR, DEPTOR).",
        "Lacks robust human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "26616262",
      "is_good_candidate": true,
      "reasons": [
        "Large, population-based prospective cohort study (Women's Health Initiative).",
        "Clear clinical endpoints (cancer incidence, cancer death).",
        "Uses robust Cox regression models with reported HRs and CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32994182",
      "is_good_candidate": false,
      "reasons": [
        "Primarily an in vitro and animal model study (mouse allograft model).",
        "Focuses on molecular mechanism (mTOR signaling and EMT).",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38866699",
      "is_good_candidate": false,
      "reasons": [
        "Abstract content is missing.",
        "Title suggests a letter, editorial, or commentary, not original research or a systematic review."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "26997714",
      "is_good_candidate": false,
      "reasons": [
        "Narrative review or commentary aimed at dermatologists.",
        "Lacks original primary data (RCT, cohort) or systematic review methodology."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "31293011",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based retrospective cohort study (N=7872).",
        "Clear clinical outcome (all-cause mortality).",
        "Uses robust time-dependent Cox models with reported HRs and 95% CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "28380674",
      "is_good_candidate": true,
      "reasons": [
        "Robust observational cohort study (N=636 diabetic NSCLC patients).",
        "Clear clinical outcome (overall survival).",
        "Uses time-dependent multivariate Cox models with reported HRs and 95% CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35545330",
      "is_good_candidate": false,
      "reasons": [
        "Narrative review or perspective article.",
        "Discusses the potential roles and mechanisms of metformin; does not present original primary data or systematic review findings."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36588385",
      "is_good_candidate": false,
      "reasons": [
        "Primarily an in vitro/cellular mechanism study.",
        "Uses a xenograft mouse model (preclinical in vivo).",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40592481",
      "is_good_candidate": false,
      "reasons": [
        "Drug development study focusing on synthesizing and testing a novel nanodelivery system.",
        "Preclinical work, tested both in vitro and in vivo (likely animal models).",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "22389381",
      "is_good_candidate": false,
      "reasons": [
        "In vitro/cellular mechanism study using MTC cell lines.",
        "Analysis of human tissue samples is very small (N=14) and focused on expression/molecular targets, not clinical outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36351567",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort study (N=466 patients).",
        "Clear clinical endpoints (ORR, PFS, OS).",
        "Provides comparative statistical analysis (p-values, survival times) suitable for quantitative synthesis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25417601",
      "is_good_candidate": false,
      "reasons": [
        "Small sample size (N=20) for a clinical study.",
        "Designed as a 'preoperative window' pilot study.",
        "Primary outcomes are surrogate markers (Ki-67, metabolomics) rather than hard long-term efficacy endpoints (OS, PFS)."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "37562095",
      "is_good_candidate": false,
      "reasons": [
        "Prospective, single-arm Phase I/II clinical trial (N=25 evaluable).",
        "Design is preliminary, primarily assessing tolerability and safety, with insufficient power and lack of a randomized control group for definitive efficacy meta-analysis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "28619830",
      "is_good_candidate": true,
      "reasons": [
        "Very large population-based cohort study (N=12,572 elderly PDAC patients).",
        "Clear clinical outcome (Overall Survival).",
        "Uses robust statistical methods (time-varying Cox models, propensity score adjustment) with reported HRs and 95% CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37620736",
      "is_good_candidate": false,
      "reasons": [
        "Very small sample size for a clinical intervention study (N=20 treated patients).",
        "Primary focus is molecular mechanism (gene expression, miRNA/PI3K/AKT pathway modulation), not robust clinical efficacy outcomes."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "35040885",
      "is_good_candidate": false,
      "reasons": [
        "Abstract content is missing.",
        "Cannot assess study methodology, population, or outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35274724",
      "is_good_candidate": false,
      "reasons": [
        "Phase I dose de-escalation study (N=40 patients).",
        "Primary focus is safety, tolerability, and pharmacokinetics (PK).",
        "Not designed or powered for efficacy inclusion in meta-analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39182906",
      "is_good_candidate": false,
      "reasons": [
        "Animal study (PCOS rats).",
        "Focuses on gene expression, hormonal balance, and biochemical mechanisms.",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40277915",
      "is_good_candidate": false,
      "reasons": [
        "In vitro/cellular mechanism study using TNBC cells.",
        "Focuses on molecular signaling pathways (HMGB1/RAGE, EMT).",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "23942093",
      "is_good_candidate": false,
      "reasons": [
        "Hybrid study: although it includes prognostic data from human patients (N=273), the therapeutic effects and mechanism are primarily validated using in vitro assays and xenograft animal models (preclinical focus)."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "36361684",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical animal study (syngeneic colon cancer mouse model).",
        "Focuses on immunological mechanisms and imaging validation.",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "28193839",
      "is_good_candidate": false,
      "reasons": [
        "In vitro/cellular mechanism study.",
        "Uses a xenographic tumor growth model in vivo (preclinical).",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36583563",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort study focusing on human patients (N=168).",
        "Clear clinical endpoints (OS, PFS, DFS).",
        "Uses appropriate statistical methods (adjusted HRs and 95% CIs) suitable for meta-analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37552599",
      "is_good_candidate": false,
      "reasons": [
        "Chemistry/Synthesis study focusing on the development of TPP+ analogs and protocols for detection.",
        "Preclinical investigation using cell lines and mouse tissue.",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "22565006",
      "is_good_candidate": false,
      "reasons": [
        "Abstract content is missing.",
        "Title suggests a methodological commentary or editorial (not original data)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38922530",
      "is_good_candidate": false,
      "reasons": [
        "In silico/Computational modeling study using pre-existing tumor cell line data (DepMap).",
        "Lacks primary human clinical outcome data from an RCT or cohort study."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40562062",
      "is_good_candidate": true,
      "reasons": [
        "Prospective comparative study in human patients (N=66).",
        "Assesses clinically relevant patient-reported outcomes (HRQOL, distress) and metabolic changes over time.",
        "Uses regression analysis to provide quantitative associations."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "37933877",
      "is_good_candidate": false,
      "reasons": [
        "Nanoparticle synthesis and testing study.",
        "In vitro/cellular model investigation (3D spheroid).",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30693913",
      "is_good_candidate": false,
      "reasons": [
        "In vitro/cellular mechanism study.",
        "Uses a xenograft mouse model in vivo (preclinical).",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "31532548",
      "is_good_candidate": false,
      "reasons": [
        "Designated as a 'Letter' (editorial comment or opinion).",
        "Lacks original primary data or systematic review methodology."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35552758",
      "is_good_candidate": false,
      "reasons": [
        "Animal study (PCOS rats).",
        "Focuses on molecular signaling pathways (lncRNA/miRNA/GLUT4 regulation).",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32410514",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study.",
        "Clear clinical outcome (cancer incidence risk).",
        "Uses standardized statistical metrics (SIRs and 95% CIs) suitable for meta-analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38185658",
      "is_good_candidate": false,
      "reasons": [
        "Animal study (mouse model of radiation-induced skin fibrosis).",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32919225",
      "is_good_candidate": true,
      "reasons": [
        "Very large population-based retrospective cohort study (N > 138,000 users).",
        "Clear clinical endpoint (overall cancer incidence).",
        "Uses robust Cox regression models and advanced statistical methods (IPTW) with reported HRs and 95% CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37676282",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective clinical cohort analysis (N=802).",
        "Clear clinical endpoints (OS, PFS, ORR) and comparison of treatment subgroups.",
        "Uses multivariate Cox analysis, providing statistical metrics suitable for inclusion."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "31346700",
      "is_good_candidate": false,
      "reasons": [
        "Narrative review, commentary, or hypothesis paper.",
        "Calls for further investigation; does not present original primary data or systematic review findings."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "22266734",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N=112,408 individuals).",
        "Clear clinical outcome (all-cause mortality after incident cancer).",
        "Uses Cox proportional hazards models with reported HRs and 95% CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34288597",
      "is_good_candidate": false,
      "reasons": [
        "Abstract content is missing.",
        "Title suggests a review or mechanistic commentary; cannot assess methodology."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32021184",
      "is_good_candidate": false,
      "reasons": [
        "Drug development study focusing on synthesizing and testing multifunctional nanoparticles.",
        "Primarily preclinical work using xenograft mouse models.",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "26132091",
      "is_good_candidate": false,
      "reasons": [
        "Focuses on developing and validating a preclinical methodology (CSC assays).",
        "Preclinical study using cell lines and mouse models (xenografts).",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "23864581",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study (N=65,754 patients).",
        "Clear clinical outcome (cancer risk reduction).",
        "Focuses on dose-dependent effects and reports HRs and 95% CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36127427",
      "is_good_candidate": false,
      "reasons": [
        "Primarily a basic science/mechanistic study using single-cell RNA-sequencing (scRNA-seq)",
        "Focus is on cell heterogeneity and receptor-ligand interactions rather than clinical intervention efficacy",
        "Retrospective clinical data mentioned is exploratory and supportive, not the main methodological study type required for meta-analysis of clinical outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39122360",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study (Merative Marketscan)",
        "Uses robust methodology (propensity score matching, Cox regression)",
        "Clear intervention/comparator groups (SGLT-2i vs oGLDs, and SGLT-2i + Metformin)",
        "Defined clinical outcomes (HCC, cirrhosis, CVD, CKD, non-liver cancer)",
        "Statistical results reported (HRs, 95% CIs)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38967919",
      "is_good_candidate": true,
      "reasons": [
        "Very large nationwide retrospective cohort study (N=1.6 million)",
        "Robust methodology utilizing propensity-score matching and Cox proportional hazards analysis",
        "Compares defined exposures (GLP-1RAs, insulin, metformin)",
        "Reports clear statistical outcomes (HRs and 95% CIs) for 13 obesity-associated cancers."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38665260",
      "is_good_candidate": false,
      "reasons": [
        "Very small sample size (N=25)",
        "Observational follow-up design, not a primary randomized trial comparison",
        "Insufficient power and high susceptibility to bias for robust inclusion in a major meta-analysis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "36907105",
      "is_good_candidate": false,
      "reasons": [
        "Predominantly a mechanistic and preclinical study (in vitro/in vivo mouse models)",
        "The associated human cohort is small (n=85) and described as 'exploratory-observational-randomized retrospective,' lacking the quality criteria for robust efficacy trials."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "33516777",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is empty, suggesting a non-primary research article (e.g., editorial, letter, or commentary)",
        "Lacks defined methodology, population, or outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38098114",
      "is_good_candidate": false,
      "reasons": [
        "Phase Ib clinical trial, primarily focused on safety and tolerability",
        "Very small sample size (N=20 enrolled)",
        "Efficacy data (PFS) is preliminary and exploratory, not powered for definitive conclusions (authors suggest further investigation in larger trials)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38926749",
      "is_good_candidate": true,
      "reasons": [
        "Large prospective cohort study (NHANES linkage) providing nationally representative data (N=3995)",
        "Robust statistical methods used (Cox proportional hazards and logistic regression)",
        "Clear, clinically relevant outcomes (cardiometabolic mortality and disease incidence)",
        "Effect sizes (HRs/ORs and CIs) are reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39408965",
      "is_good_candidate": false,
      "reasons": [
        "Relatively small sample size for a cohort comparison (PCOS n=69, controls n=18)",
        "Primary focus is mechanistic (changes in gut microbiota and SCFAs), rather than core clinical endpoints (e.g., birth rates, major morbidity)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "37314979",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study (N=4851 esophageal cancer patients)",
        "Clear exposure (metformin use) and outcome (all-cause and disease-specific mortality)",
        "Robust statistical analysis (multivariable Cox regression) including dose-response trend",
        "Statistical results (HRs and 95% CIs) are reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29860724",
      "is_good_candidate": false,
      "reasons": [
        "Described as a 'preliminary observation' and retrospective chart review",
        "Focuses heavily on surrogate biomarkers of aging (ferritin, HbA1c, lymphocyte counts) rather than definitive cancer outcomes",
        "Implied limitations in sample size and methodology typical of preliminary studies."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "38374053",
      "is_good_candidate": false,
      "reasons": [
        "Randomized controlled trial (RCT) but severely limited by small size (N=60 recruited, N=36 completed)",
        "Short treatment duration (12 weeks)",
        "Authors explicitly state findings need to be confirmed in PCOS study populations with larger sample sizes, suggesting lack of sufficient power."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "35220243",
      "is_good_candidate": false,
      "reasons": [
        "Small retrospective cohort study (N=40 patients)",
        "Primarily focused on assessing safety (Phase Ib characteristics) of a combination therapy",
        "Lack of robust control group for efficacy comparison of metformin versus non-metformin diabetic controls."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40601368",
      "is_good_candidate": true,
      "reasons": [
        "Large nationwide population-based cohort study",
        "Rigorous methodological approaches employed (1:1 propensity score matching, time-dependent Cox models, Fine-Gray competing risk analysis)",
        "Clear exposure/outcome definitions (CRC risk, all-cause mortality), with dose-response assessment",
        "Statistical results (aHRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32446797",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based case-control study with data from two large cohorts",
        "Clear outcomes (risk reduction for breast and colorectal cancer)",
        "Robust statistical methods used (multivariate analysis, adjusted for multiple confounders)",
        "Effect sizes (ORs, CIs) are reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37659962",
      "is_good_candidate": false,
      "reasons": [
        "Highly mechanistic focus involving preclinical models (mouse models, cell lines) and biomarker correlation (NKX3.1 status)",
        "Clinical data serves primarily for correlation with a specific molecular marker, not robust general population efficacy assessment."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "37399061",
      "is_good_candidate": false,
      "reasons": [
        "Primarily a mechanistic study focusing on resistance mechanisms (insulin feedback) using mouse models",
        "Retrospective clinical evaluation derived from a small Phase 2 trial is secondary and biomarker-focused, not intended for robust clinical efficacy analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "26973204",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study (UK National Cancer Data Repository, N=533/1350 analyses)",
        "Clear outcome (lung cancer-specific mortality) and exposure groups",
        "Robust statistical analysis using Cox regression models",
        "Statistical results (adjusted HRs, CIs) provided."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38366810",
      "is_good_candidate": true,
      "reasons": [
        "Cohort study derived from high-quality primary data (two randomized trials, PregMet2 and Labour Progression Study)",
        "Clear comparison between metformin and placebo in the PCOS subgroup",
        "Defined patient-reported outcome measure (Childbirth Experience Questionnaire, CEQ scores)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "27496094",
      "is_good_candidate": true,
      "reasons": [
        "Very large retrospective cohort study (N=21,352 U.S. Veterans)",
        "Robust statistical methodology (multivariable Cox models) adjusted for diabetic severity and other risk factors",
        "Clear primary outcome (Overall Survival) comparing metformin users to non-metformin users",
        "Statistical results (HRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "23962874",
      "is_good_candidate": true,
      "reasons": [
        "Moderately large cohort study (N=9486 T2DM patients)",
        "Uses Cox proportional hazards regression to examine cancer risk (breast, prostate, colon)",
        "Compares multiple glucose-lowering medications (metformin, insulin, sulfonylurea) and glycemic control levels."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "36178848",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based retrospective cohort study (N=1971 patients)",
        "Employs robust statistical adjustment technique (Inverse Probability Treatment Weighting, IPTW) to balance covariates",
        "Clear outcomes (PCa-related mortality and all-cause mortality)",
        "Statistical results (wHRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34373584",
      "is_good_candidate": true,
      "reasons": [
        "Extremely large population-based cohort study (N=388,760 men)",
        "Utilizes robust methodology including time-dependent variables in Cox proportional hazard models",
        "Clear outcomes (PC incidence and mortality) assessed over a 10-year period",
        "Statistical results (aHRs, CIs) provided."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30385499",
      "is_good_candidate": false,
      "reasons": [
        "Abstract content is missing, suggesting a non-primary research article (Letter), lacking defined methodology and statistical results."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40595354",
      "is_good_candidate": true,
      "reasons": [
        "Very large retrospective cohort study (N=63,907 women) using SEER-Medicare data",
        "High-quality methodological design using Inverse Probability of Treatment Weighting (IPTW-PS) and competing-risks models",
        "Clear outcomes (all-cause and cancer-specific mortality)",
        "Statistical results (HRs, CIs) provided."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "26721670",
      "is_good_candidate": true,
      "reasons": [
        "Population-based retrospective cohort study using administrative databases",
        "Employs appropriate statistical techniques for time-varying exposure and mortality (Fine-Gray competing risk and Cox regression)",
        "Examines dose-dependent relationship for clear mortality outcomes (cancer-specific and overall)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "21812892",
      "is_good_candidate": true,
      "reasons": [
        "Moderately large retrospective cohort study (N=3685 T2DP)",
        "Uses robust methodology, including Cox regression for competing risks and adjustment using propensity scores",
        "Clear outcomes (cancer and other-than-cancer mortality)",
        "Statistical results (HRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40532471",
      "is_good_candidate": true,
      "reasons": [
        "Large nationwide retrospective cohort study (N=753 patients) providing real-world evidence (RWE)",
        "Uses multivariate analysis to control for comorbidities and disease aggressiveness",
        "Clear survival outcomes (OS and PFS) related to metformin comedication."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "22778198",
      "is_good_candidate": true,
      "reasons": [
        "Very large population-based retrospective cohort study (N=~1 million individuals followed)",
        "Robust statistical methods (Cox regression, adjustment for confounders and detection bias)",
        "Clear outcome (colon cancer risk) and assessment of duration/dose-dependent effect",
        "Statistical results (adjusted RRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "23918942",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based retrospective cohort study (N=3837 patients)",
        "Employs robust methodology using a time-varying Cox proportional hazard model for cumulative duration exposure (dose-dependent analysis)",
        "Clear outcomes (PC-specific and all-cause mortality)",
        "Statistical results (HRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "19717820",
      "is_good_candidate": false,
      "reasons": [
        "Abstract content is missing, suggesting a non-primary research article (likely a commentary or editorial), lacking defined methodology and statistical results."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38490274",
      "is_good_candidate": true,
      "reasons": [
        "Large nationwide nested case-control study (N=1737 cases, N=8685 controls)",
        "Rigorous methodology (incidence-density matching, conditional logistic regression)",
        "Clear exposure (GLP-1RA use) and outcome (glaucoma incidence), with duration analysis",
        "Statistical results (HRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "28918830",
      "is_good_candidate": false,
      "reasons": [
        "Relatively small retrospective cohort study for survival analysis (Colon N=202, Lung N=180)",
        "Comparison group definition is weak and susceptible to confounding ('controls taking any medication except MF')."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "36662841",
      "is_good_candidate": false,
      "reasons": [
        "Primary focus is on Bacille Calmette Guerin (BCG) intervention, not metformin efficacy",
        "Mixed methodology includes small retrospective clinical cohorts and weak ecological analysis of global data",
        "Metformin is discussed primarily as a potential confounding/inhibitory factor."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "24133632",
      "is_good_candidate": false,
      "reasons": [
        "Retrospective cohort study with severely imbalanced comparison groups (Metformin group N=20, Non-diabetic N=422)",
        "Small key subgroup size dramatically increases the risk of bias and limits power for robust meta-analysis comparison."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40323038",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort analysis (N=4882 patients) from a specialized cancer center",
        "Utilizes univariable and multivariable analysis to assess risk factors",
        "Clear, clinically relevant outcome (lymphedema risk after ALND)",
        "Statistical results (HRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34085799",
      "is_good_candidate": true,
      "reasons": [
        "Nationwide population-based cohort study (Korean NHIS Data)",
        "Robust statistical methods (Cox proportional hazards regression, multivariable adjustment)",
        "Clear survival outcomes (OS, CSS) including analysis based on long-term use",
        "Statistical results (HRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40268162",
      "is_good_candidate": true,
      "reasons": [
        "Very large retrospective comparative cohort study (N=74,975 matched pairs)",
        "Robust methodological technique (1:1 propensity score matching, Cox models) to compare first-line therapies (SGLT2i vs Metformin)",
        "Clear, clinically relevant outcomes (dementia incidence, mortality)",
        "Statistical results (aHRs, CIs) provided."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38114915",
      "is_good_candidate": true,
      "reasons": [
        "High-quality retrospective study using propensity score matching to balance cohorts",
        "Clear comparative intervention (metformin mono vs dual therapy with SGLT2-I)",
        "Defined clinical outcomes (mortality, hepatic decompensation, HCC occurrence)",
        "Statistical results (HRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34811499",
      "is_good_candidate": true,
      "reasons": [
        "Large cohort study (N=4572 men with advanced PCa)",
        "Utilizes robust statistical methods (multivariable, time-varying Cox models) appropriate for longitudinal drug exposure",
        "Clear survival outcomes (all-cause and PCa-specific mortality)",
        "Statistical results (HRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35079115",
      "is_good_candidate": false,
      "reasons": [
        "Phase 2 randomized controlled trial (RCT)",
        "Very small sample size (N=29 enrolled)",
        "The trial was stopped early due to predicted inability to achieve the primary endpoint, indicating insufficient power/efficacy for robust synthesis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "36400170",
      "is_good_candidate": true,
      "reasons": [
        "Large observational retrospective study using EHR data from 52 hospitals",
        "Used Inverse Probability Score Weighting (IPSW) for robust covariate balancing",
        "Clear clinical outcome (COVID-19 severity and mortality)",
        "Statistical results (ORs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27211307",
      "is_good_candidate": true,
      "reasons": [
        "Multicenter retrospective study across 8 centers in 2 countries",
        "Moderate sample size (N=108) with balanced comparison groups",
        "Multivariate analysis performed to assess metformin use as an independent factor for survival",
        "Clear outcomes (PFS, OS) reported with statistical results (HRs, P-values)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "37452329",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N=3742 BC patients)",
        "Rigorous statistical methodology (multivariable Cox models) and sensitivity analysis using propensity-score matching",
        "Clear survival outcomes (OS, DSS, RFS) related to chronic medication use",
        "Statistical results (HRs, CIs) provided."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32182614",
      "is_good_candidate": false,
      "reasons": [
        "Primary outcome assessed is a genomic biomarker (Oncotype DX Recurrence Score), not a hard clinical endpoint (e.g., recurrence or survival)",
        "Limited clinical utility for meta-analyses focused on efficacy/mortality."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "33848178",
      "is_good_candidate": false,
      "reasons": [
        "Study focuses on a highly specific and high-risk patient population (Heart Transplant recipients)",
        "Key subgroup of metformin users is very small (N=52), limiting statistical power and generalizability."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "24215316",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study (N=1058 diabetic women with breast cancer)",
        "Uses multivariate Cox regression to assess survival outcomes (all-cause and cancer-specific mortality)",
        "Includes dose/duration stratification for refined analysis",
        "Statistical results (HRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29956875",
      "is_good_candidate": true,
      "reasons": [
        "Extremely large retrospective cohort study (N=43,800 matched cohort)",
        "Highly rigorous statistical methodology (Propensity Score matching, Cox regression with Inverse Probability of Treatment Weighting, dose-response analysis)",
        "Clear outcome (HCC risk reduction)",
        "Statistical results (HRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27519177",
      "is_good_candidate": true,
      "reasons": [
        "Moderate-to-large retrospective cohort study (N=1106 patients)",
        "Clear defined outcome (Overall Survival) in advanced NSCLC patients",
        "Robust statistical analysis (multivariate Cox proportional hazard model) controlling for confounding factors."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "30753459",
      "is_good_candidate": true,
      "reasons": [
        "Very large cohort study (N=55,629 T2DM patients)",
        "Employs highly advanced and robust statistical methodology (Marginal Structural Models with IPTW) specifically appropriate for analyzing time-varying drug exposure with time-varying confounders",
        "Clear cancer risk outcomes (HRs, CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "24898303",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N=95,820) designed to emulate an intention-to-treat trial.",
        "Clear comparative exposure (Metformin vs. Sulfonylurea) and well-defined outcome (incident cancer diagnosis).",
        "Uses robust statistical methods (Cox proportional hazards models) and reports effect sizes (HRs, CIs)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35533029",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort study derived from a randomized trial population.",
        "Clear exposure (sulfonylureas vs. non-users) and measurable outcomes (SCC and BCC development).",
        "Provides appropriate statistical measures (HRs and CIs) after controlling for confounders."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "32798709",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N=74,984) using high-quality data (VHA).",
        "Employs advanced statistical techniques (Marginal structural models and propensity-matching) to control for confounding.",
        "Clear clinically relevant outcomes (mortality, HCC, hepatic decompensation) and reports effect sizes (HRs, CIs)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34779535",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N=85,963) with long follow-up (mean 10.3 years).",
        "Focuses on a specific high-risk population (NAFLD and DM) with clear outcomes (HCC risk).",
        "Uses appropriate statistical methods (Cox proportional hazards models) and reports HRs and CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "33610593",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based case-control study (N > 76,000 participants).",
        "Clear exposure (metformin use) and defined outcomes (BCC, SCC).",
        "Provides quantifiable effect sizes (ORs, CIs) calculated using conditional logistic regression."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "37125965",
      "is_good_candidate": true,
      "reasons": [
        "Large, multi-institutional cohort study (N=1,395 patients) focusing on a specific clinical intervention (Immune Checkpoint Blockade).",
        "Clear survival outcomes (OS and PFS).",
        "Uses multivariable analysis and reports adjusted effect sizes (HRs, CIs)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34260511",
      "is_good_candidate": true,
      "reasons": [
        "Clear retrospective cohort design with defined population (sporadic VS patients) and outcome.",
        "Uses a measurable primary outcome (volumetric tumor growth defined by >20% increase).",
        "Provides statistical results including HRs and CIs, suitable for pooling regardless of null findings."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "37889443",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort study focusing on survival in a severe cancer type (glioblastoma).",
        "Clear outcome (overall survival) and statistical analysis (Cox regression, Kaplan-Meier).",
        "Provides adjusted effect sizes (aHRs, CIs) for inclusion."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "27587088",
      "is_good_candidate": true,
      "reasons": [
        "Very large retrospective cohort study (N > 300,000) using national insurance data.",
        "Robust statistical methodology (Cox regression with inverse probability of treatment weighting).",
        "Clear exposure, outcome (gastric cancer risk), and detailed dose-duration analysis (HRs, CIs)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "33626532",
      "is_good_candidate": true,
      "reasons": [
        "Multi-center retrospective cohort study (N=537) focused on a specific cancer type (Cholangiocarcinoma).",
        "Clear clinical endpoints (Disease-Free Survival and Overall Survival).",
        "Provides necessary statistical data (HRs, CIs) for meta-analysis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "40239400",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort study (single center, N=953) focused on complications (IMC) and survival in ICI patients.",
        "Clear methodology and defined clinical outcomes (IMC incidence, OS).",
        "Provides statistical comparisons (p-values, survival data) and is relevant to drug toxicity/efficacy."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "33058005",
      "is_good_candidate": false,
      "reasons": [
        "The article is primarily a discussion or hypothesis-generating piece based on preliminary evidence.",
        "It focuses on a potential molecular mechanism (IRS1 pathway) and explicitly calls for future prospective RCTs.",
        "Does not report primary clinical outcomes or robust effect sizes from a controlled trial or large cohort."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30281009",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective study (N=2,441) using an institutional database.",
        "Clear defined intervention (radiation therapy) and clinically relevant outcomes (BCR and OS).",
        "Uses rigorous statistical methods (Kaplan-Meier, Cox regression, multivariate analysis) and reports HRs and CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34929693",
      "is_good_candidate": true,
      "reasons": [
        "Multicentre retrospective cohort study using a large number of hospital databases (N=9).",
        "Investigates chemopreventive effects on specific cancer subtypes (ESCC, EAC).",
        "Provides adjusted effect sizes (aORs) and p-values for clear associations."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "32159875",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort study comparing matched arms (metformin users vs other antidiabetic agents).",
        "Clear definition of patient population (solid organ transplant recipients) and primary outcome (malignancy first occurrence).",
        "Provides survival curves and subgroup analyses, suitable for pooling."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "33725979",
      "is_good_candidate": true,
      "reasons": [
        "Very large, nationwide population-based retrospective cohort study (Korean NHIS, N > 9,000 diabetic survivors).",
        "Clear primary outcome (all-cause mortality in cancer survivors).",
        "Uses robust statistical methods (Cox models, stratified analysis) and reports adjusted HRs and CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32532851",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N=20,577) comparing risks of third-line antidiabetic medications.",
        "Uses strong statistical methodology (Propensity-score weighting) to reduce confounding.",
        "Clear outcomes (cancer incidence, cancer mortality, all-cause mortality) with HRs and CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36547172",
      "is_good_candidate": true,
      "reasons": [
        "Population-based retrospective cohort study focused on a defined cancer population (Head and Neck Melanoma, N=382).",
        "Clear survival outcome (Recurrence-Free Survival).",
        "Uses robust multivariate Cox regression analysis and reports HRs and CIs."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "33911196",
      "is_good_candidate": false,
      "reasons": [
        "This article is identified as a comment/editorial discussing the complexity of associations.",
        "It does not present primary data, original results, or formal statistical analysis suitable for meta-analysis pooling."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37077173",
      "is_good_candidate": true,
      "reasons": [
        "Nationwide retrospective cohort study (Taiwan NHIRD) with a large matched cohort (N=6,222).",
        "Clear clinical outcomes (5-year overall survival and risk of liver metastasis).",
        "Uses appropriate methodology (Cox regression with time-dependent covariates) and reports HRs and CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "26013675",
      "is_good_candidate": true,
      "reasons": [
        "Nested case-control study design, which is a methodologically strong approach within a cohort.",
        "Clear exposure (various antidiabetic drugs) and outcome (HCC risk).",
        "Provides statistical measures (ORs, CIs) and analyzes duration dependency."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "29453032",
      "is_good_candidate": true,
      "reasons": [
        "Population-based observational study using cancer registry and claims data.",
        "Clear survival outcomes (Overall Survival and Cancer-Specific Mortality).",
        "Uses appropriate time-dependent Cox regression models and reports HRs and CIs."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "36008432",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort analysis using Propensity Score (PS) matching to balance covariates.",
        "Clear focus on treatment response (TACE) and local recurrence (LTR) in HCC patients.",
        "Provides robust statistical results (ORs and HRs with CIs) on treatment efficacy."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "28736111",
      "is_good_candidate": true,
      "reasons": [
        "Prospective follow-up cohort study investigating malignancy risk after heart transplantation.",
        "Metformin treatment and DM status are assessed as time-dependent factors.",
        "Uses robust multivariate analysis and reports significant HRs and CIs over 15 years of follow-up."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "31770138",
      "is_good_candidate": true,
      "reasons": [
        "Very large case-control study (N > 460,000) using US Veterans EHR data.",
        "Clear exposure (metformin use) and outcome (CRC risk, stratified by site).",
        "Uses multivariable and multinomial logistic regression, reporting ORs and CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30229901",
      "is_good_candidate": true,
      "reasons": [
        "Very large population-based cohort study (N > 223,000 incident cancer patients).",
        "Uses strong methodological controls including Propensity Score (PS) matching.",
        "Clear outcome (risk of new-onset metastatic cancer) and reports adjusted HRs and CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35134807",
      "is_good_candidate": false,
      "reasons": [
        "The study is primarily focused on identifying and validating a biomarker (HSPA6) derived from mechanistic pathways, not on metformin's primary clinical effect.",
        "Includes initial in vitro/NGS analysis.",
        "The clinical cohort (N=83) is small and used to assess biomarker prognostic value, not metformin outcome association in a large cohort."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "26897929",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N=913) focused on a specific cancer type (Biliary Tract Cancer).",
        "Clear survival outcomes (RFS and OS).",
        "Provides necessary statistical data (HRs, CIs from multivariable analysis) for meta-analysis pooling."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "33464703",
      "is_good_candidate": false,
      "reasons": [
        "This is a pilot randomized controlled trial with a very small sample size (N=30).",
        "The primary endpoint (HCL levels measured by MRS) is an intermediate metabolic outcome, not a long-term clinical or oncological endpoint.",
        "Insufficient power for meta-analysis of survival/incidence."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "27789181",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective review (N=3,217) from an institutional database.",
        "Detailed subgroup analysis based on specific antidiabetic drug classes (metformin vs. insulin vs. none).",
        "Uses advanced competing risk regression models and reports subdistribution hazard ratios (sHRs, CIs) for survival and failure."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30941974",
      "is_good_candidate": false,
      "reasons": [
        "Relatively small sample size (N=518).",
        "The primary endpoint is prostate cancer detection/grade at biopsy, which is prone to selection and screening bias, rather than true incidence or survival in a general population cohort.",
        "Limited statistical power for robust meta-analysis inclusion."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "29165598",
      "is_good_candidate": false,
      "reasons": [
        "The study population (offspring born to mothers with PCOS) and primary outcomes (fetal growth and birth anthropometrics) are irrelevant to the meta-analysis topic (adult cancer risk or survival).",
        "This is a post-hoc analysis focused on maternal/fetal health."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32424261",
      "is_good_candidate": true,
      "reasons": [
        "Case-control design assessing the risk of overall and high-grade prostate cancer (N=3,481).",
        "Clear definition of exposure (metformin use) and outcome.",
        "Provides necessary statistical measures (ORs, CIs) for meta-analysis of association studies."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "30084749",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective review comparing metformin users versus non-metformin antidiabetic drug users (N=321 CRC/DM patients).",
        "Clear survival outcomes (Overall Survival and Progression-Free Survival).",
        "Provides adjusted HRs and CIs, suitable for pooling regional data."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "34312687",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective analysis focused on treatment efficacy (Y-90 RS) in HCC patients (N=106).",
        "Clear outcomes (tumor response by mRECIST and OS).",
        "Uses multivariate logistic regression and provides survival analysis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "31583436",
      "is_good_candidate": false,
      "reasons": [
        "This is a Phase I trial primarily designed to assess safety, dose-limiting toxicities (DLTs), and pharmacodynamics (AMPK).",
        "Sample size (N=100) is small for efficacy comparison, and secondary endpoints (response rates, stable disease) lack the definitive power of a Phase III study."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25899185",
      "is_good_candidate": false,
      "reasons": [
        "The study population (pregnant women with PCOS) and outcome (Gestational Diabetes Mellitus) are irrelevant to the meta-analysis topic (adult cancer incidence or survival).",
        "Focuses on obstetric and metabolic outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37270169",
      "is_good_candidate": false,
      "reasons": [
        "Primarily a mechanistic and preclinical study involving in vitro cell line experiments, molecular analysis (qPCR, Western blotting), and animal models ('in vivo').",
        "Clinical data component is limited (retrospective SUVmax correlation) and not the primary focus of robust clinical outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29246826",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N=16,237 matched pairs) using national database.",
        "Uses strong methodological control (propensity score weighted Cox regression).",
        "Clear outcome (skin cancer risk) and provides detailed dose/duration analysis (HRs, CIs)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37227368",
      "is_good_candidate": true,
      "reasons": [
        "High-quality observational study using methodologically rigorous approach (Target Trial Emulation).",
        "Based on large population-based linked electronic health records (UK).",
        "Clear outcomes (total cancer and site-specific cancer incidence) and reports risk differences/CIs using IPTW."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37735822",
      "is_good_candidate": false,
      "reasons": [
        "The primary exposures examined are GLP-1RAs and DPP-4 inhibitors compared to SGLT2 inhibitors.",
        "Metformin serves only as a background add-on therapy, not the primary exposure whose effect is being analyzed for meta-analysis inclusion."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "38308321",
      "is_good_candidate": false,
      "reasons": [
        "This article is a protocol description for a Phase II randomized clinical trial (MILI study).",
        "It provides methodology and endpoints but contains no finalized data, results, or effect sizes for inclusion in a meta-analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39790228",
      "is_good_candidate": true,
      "reasons": [
        "Very large retrospective cohort study (N=88,713) of US veterans.",
        "Direct comparison of Metformin versus Sulfonylurea (active comparator).",
        "Uses strong statistical methodology (Propensity Score-Matched IPTW, Cox models) and reports HRs and CIs for cancer subtypes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34443319",
      "is_good_candidate": false,
      "reasons": [
        "This is primarily an in vitro and mechanistic study focusing on the chemical structure (metal complex formation) and antiproliferative effects in cancer cell lines.",
        "It does not report human clinical outcomes (incidence or survival)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "20980415",
      "is_good_candidate": true,
      "reasons": [
        "Nested case-control study design within a defined cohort (insulin-treated T2DM patients).",
        "Clear outcome (incident cancer) and exposure (metformin use).",
        "Provides effect sizes (ORs, CIs) adjusted for confounders."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "40290515",
      "is_good_candidate": false,
      "reasons": [
        "This is a systematic review and Network Meta-Analysis (NMA), which summarizes primary data.",
        "Meta-analyses typically include only primary research studies (RCTs or observational cohorts/case-controls), not other reviews/meta-analyses."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30623338",
      "is_good_candidate": true,
      "reasons": [
        "Community-based retrospective cohort study (N=2,353) with clear comparative groups (monotherapy vs. non-users).",
        "Clear outcome (cancer incidence) and statistical analysis (adjusted HRs, CIs).",
        "Provides real-world evidence of association."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "34006970",
      "is_good_candidate": false,
      "reasons": [
        "In vitro study using colorectal cancer cell lines.",
        "Focuses on metabolic phenotype and mechanistic drug response under differing glucose conditions.",
        "Lack of human clinical data on incidence or survival."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25575041",
      "is_good_candidate": false,
      "reasons": [
        "The endpoint is prostate cancer diagnosis and grade following a specific, invasive biopsy procedure (template-guided mapping biopsy).",
        "This endpoint is highly susceptible to screening and selection bias rather than being a measure of population-level incidence or overall survival.",
        "Small sample size for assessing cancer risk association (N=1034)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "25419576",
      "is_good_candidate": true,
      "reasons": [
        "Large cohort study (N=23,394) with long follow-up (9 years).",
        "Methodologically rigorous, addressing time-related biases by using Lexis tabulation and Poisson regression.",
        "Clear outcome (cancer incidence) and provides RRs and CIs."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36428689",
      "is_good_candidate": false,
      "reasons": [
        "In vitro study using cancer cell lines.",
        "Preclinical animal study (mouse xenografts).",
        "Focuses on molecular mechanisms (NAMPT inhibition)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38971341",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical animal study (SDT rats).",
        "Investigates the effect of a plant extract (CGDCM), not a standard pharmaceutical intervention."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29977599",
      "is_good_candidate": false,
      "reasons": [
        "Primarily in vitro study investigating molecular mechanisms (Wnt signaling, intracellular acidification).",
        "Includes a mouse xenograft model (preclinical)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38893174",
      "is_good_candidate": false,
      "reasons": [
        "In vitro cell line study (CRC cells).",
        "Focuses on transcriptomics and molecular mechanism analysis (miRNA and gene pairs)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "28732480",
      "is_good_candidate": false,
      "reasons": [
        "This is a description of an ongoing clinical trial protocol ('currently open to recruitment'), lacking final outcome data.",
        "The primary endpoint is surrogate biological markers (FASN/AMPK pathway expression) rather than hard clinical outcomes."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "31597663",
      "is_good_candidate": false,
      "reasons": [
        "Primary findings derived from animal model (mice).",
        "Small human observational cohort focusing on tissue histology and biological markers (fibrosis, T-cell ratios)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "26291325",
      "is_good_candidate": false,
      "reasons": [
        "In vitro cell line study (breast cancer cells).",
        "Focuses on molecular mechanisms (PKM2, AMPK/mTOR pathway modulation)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25358675",
      "is_good_candidate": true,
      "reasons": [
        "Prospective population-based screening trial (ERSPC Aarau).",
        "Analyzes clinical outcomes (PCa incidence, overall survival).",
        "Reports robust statistical analysis (OR, 95% CI)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "26472977",
      "is_good_candidate": false,
      "reasons": [
        "This is a systematic review and meta-analysis (secondary source data), not a primary clinical or epidemiological study suitable for pooling individual data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36766896",
      "is_good_candidate": false,
      "reasons": [
        "Appears to be a simple survey/questionnaire-based observational study.",
        "Lacks clear definition of control group, rigorous statistical methodology, and sufficient quantitative outcomes in the abstract for pooling."
      ],
      "confidence_score": 0.85
    },
    {
      "pmid": "25502158",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort study spanning 20 years (N=583 patients).",
        "Defined clinical outcome (progression to esophageal adenocarcinoma).",
        "Uses multivariate logistic regression and reports statistical findings (P-values)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "32601620",
      "is_good_candidate": false,
      "reasons": [
        "Small pilot/preliminary randomized study (N=41).",
        "Primarily focuses on translational correlates (AMPK phosphorylation) and safety (DLT), not large-scale efficacy data.",
        "Presents results as a sub-group analysis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "40243198",
      "is_good_candidate": true,
      "reasons": [
        "Large-scale, long-term Randomized Controlled Trial (RCT) follow-up (DPP/DPPOS, N=3,234).",
        "Clear intervention (Metformin vs. Placebo/ILS).",
        "Measures hard clinical endpoint (Total Cancer Incidence) over 21 years.",
        "Reports robust statistical analysis (HR, 95% CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32532664",
      "is_good_candidate": true,
      "reasons": [
        "Large-scale retrospective cohort study (N=336,168) using national registry data.",
        "Analyzes hard clinical outcome (lung cancer incidence).",
        "Reports Hazard Ratios (HR) and Confidence Intervals (CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25681088",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical animal study (rat and mouse models).",
        "Investigates mammary carcinogenesis models."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36604960",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based retrospective cohort study (N>130,000).",
        "Clear clinical outcome (cervical cancer incidence) in a defined population (newly diagnosed T2DM).",
        "Reports robust statistical measures (HR, CI) and dose-response findings."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "22611195",
      "is_good_candidate": false,
      "reasons": [
        "Basic science/mechanistic study focused on genome-wide analysis of translational targets.",
        "Lacks human clinical outcome data (incidence or survival)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25377470",
      "is_good_candidate": false,
      "reasons": [
        "In vitro metabolic studies.",
        "Preclinical animal study (mice) investigating dietary manipulation."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25674734",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study (N=71,847) using national database.",
        "Analyzes clinical outcomes (HCC and non-liver cancers).",
        "Reports adjusted Hazard Ratios (HR) and Confidence Intervals (CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30385498",
      "is_good_candidate": false,
      "reasons": [
        "The article is identified as a 'Letter', indicating it is an opinion, editorial, or commentary, lacking primary data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27534967",
      "is_good_candidate": false,
      "reasons": [
        "Primarily an in vitro/cell line study investigating molecular mechanisms (EMT, epigenetics, AMPK/ERK axis).",
        "Translational validation is limited to leukocytes from diabetic subjects."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "24074896",
      "is_good_candidate": false,
      "reasons": [
        "This is a hypothesis paper, not a primary research study reporting data or outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27689018",
      "is_good_candidate": false,
      "reasons": [
        "In vitro study using cancer cell lines.",
        "Investigates Canagliflozin, a drug mechanistically related but chemically distinct from Metformin, and is not suitable for a Metformin-specific meta-analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25913129",
      "is_good_candidate": true,
      "reasons": [
        "Very large retrospective cohort study (N=478,921) using national registry data.",
        "Clear clinical outcome (endometrial cancer risk).",
        "Uses robust statistical modeling (time-dependent Cox regression, PS-adjustment) and reports HR and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "28154203",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical animal study (rat model of mammary carcinogenesis).",
        "Focuses on surrogate markers (OCT2 protein expression, tumor volume regression)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25804611",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical animal study (rat model).",
        "Investigates chemically induced mammary carcinogenesis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25820555",
      "is_good_candidate": true,
      "reasons": [
        "Very large retrospective cohort study (N=479,475) using national registry data.",
        "Clear clinical outcome (ovarian cancer incidence).",
        "Uses robust statistical modeling (time-dependent approach) and reports HR and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38520039",
      "is_good_candidate": true,
      "reasons": [
        "Large prospective cohort study (N=185,181, Nurses' Health Studies).",
        "Substantial person-years of follow-up (3.3 million).",
        "Analyzes hard clinical outcome (breast cancer incidence) and reports HR and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "21800293",
      "is_good_candidate": true,
      "reasons": [
        "Clinical retrospective cohort study (N=1448) focused on a specific cancer subtype (TNBC).",
        "Analyzes hard survival outcomes (DMFS, RFS, OS).",
        "Uses Cox proportional hazards models and reports HR and CI."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "26537234",
      "is_good_candidate": true,
      "reasons": [
        "Very large retrospective cohort study (N=482,033) using national registry data.",
        "Studies breast cancer incidence and statistically evaluates the role of metformin as a risk modifier.",
        "Reports HRs and CIs."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "23641353",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort study (N=1,320 patients) with clinical outcome (cancer incidence).",
        "Uses multiple regression analysis and compares metformin dosage groups (quantitative data).",
        "Provides primary epidemiological data."
      ],
      "confidence_score": 0.85
    },
    {
      "pmid": "31269196",
      "is_good_candidate": true,
      "reasons": [
        "Very large population-based cohort study (N>315,000).",
        "Uses robust statistical methodology (time-dependent Cox model, weighted cumulative exposure) to minimize bias.",
        "Analyzes cancer incidence across major sites and reports HR and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "22751115",
      "is_good_candidate": false,
      "reasons": [
        "Primarily an animal study (mice) and in vitro study focused on molecular mechanisms (AMPK, DNA repair).",
        "Preclinical investigation of skin tumorigenesis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36168905",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based retrospective cohort study using national database.",
        "Analyzes specific clinical outcome (pancreatic cancer incidence).",
        "Uses Cox regression and reports HR and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "23966577",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study using nested case-control methodology.",
        "Rigorous statistical analysis (conditional logistic regression, accounted for latency).",
        "Clear clinical outcome (colorectal cancer incidence) and reports RR and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "22994747",
      "is_good_candidate": false,
      "reasons": [
        "In vitro study using cancer cell lines (Hep-G2).",
        "Preclinical animal xenograft model (in vivo tumor growth).",
        "Focuses on molecular mechanisms (mTOR, apoptosis)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "26405648",
      "is_good_candidate": false,
      "reasons": [
        "This is a review article summarizing clinical observations, animal studies, and cell line research.",
        "Does not present new primary data for pooling."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25051408",
      "is_good_candidate": true,
      "reasons": [
        "Large prospective cohort study (N=88,107, Women's Health Initiative).",
        "Analyzes endometrial cancer risk and reports multivariate Cox regression results (HR, CI).",
        "Addresses major confounders (BMI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "23137378",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort study using large UK database (CPRD).",
        "Compares cancer incidence between initial metformin and sulfonylurea exposure.",
        "Reports standardized incidence rates, adjusted HR, and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "31827719",
      "is_good_candidate": false,
      "reasons": [
        "This is a theoretical/conceptual paper or review.",
        "Focuses on the mediator role of glucose metabolism in aging and cancer, lacking new primary epidemiological or clinical trial data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30042822",
      "is_good_candidate": false,
      "reasons": [
        "Computational modeling/theoretical study.",
        "Lacks primary clinical or epidemiological data collection."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32938643",
      "is_good_candidate": true,
      "reasons": [
        "Large nationwide retrospective cohort study using robust methodology (time-dependent variables).",
        "Analyzes hard clinical outcomes (gastric cancer incidence and mortality).",
        "Reports HR and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "21752291",
      "is_good_candidate": true,
      "reasons": [
        "Sub-analysis of a large prospective Randomized Controlled Trial (RCT) (D2C cohort, N=26,742).",
        "Measures cancer incidence using record linkage.",
        "Reports SIRs and HRs with CI."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "27026681",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N=76,733 male veterans).",
        "Uses robust statistical methods (Cox model, propensity score adjustment).",
        "Analyzes clinical outcome (prostate cancer incidence) and reports HR and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36420887",
      "is_good_candidate": false,
      "reasons": [
        "The primary exposure studied is analgesic use (not metformin).",
        "Metformin adherence is only a secondary factor/covariate in the analysis."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "25201464",
      "is_good_candidate": true,
      "reasons": [
        "Very large retrospective cohort study (N=395,481) using national registry data.",
        "Clear clinical outcome (prostate cancer incidence).",
        "Uses robust statistical modeling (time-dependent Cox regression, PS-adjustment) and reports HR and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "28645427",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N=92,366) combined with nested case-control analysis.",
        "Rigorous statistical methodology (Poisson and conditional logistic regression).",
        "Measures clinical outcome (endometrioid EC incidence) and reports HR and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "22614062",
      "is_good_candidate": false,
      "reasons": [
        "In vitro cell line experiments.",
        "Preclinical animal xenograft model (murine model).",
        "Lacks human clinical outcome data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "21509444",
      "is_good_candidate": true,
      "reasons": [
        "Sub-analysis of a large, international Randomized Controlled Trial (RCT) (ADVANCE trial, N=11,140).",
        "Analyzes hard clinical outcomes (cancer incidence and mortality).",
        "Reports HR and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "22923670",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study using nested case-control methodology (N=115,923).",
        "Rigorous statistical analysis (conditional logistic regression) adjusted for smoking.",
        "Clear clinical outcome (lung cancer incidence) and reports RR and CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39991135",
      "is_good_candidate": false,
      "reasons": [
        "Animal/in vitro study (fission yeast S. pombe)",
        "Focuses on genetic and molecular mechanisms, lacking human clinical outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35783012",
      "is_good_candidate": false,
      "reasons": [
        "In vitro study using bladder cancer cells",
        "Focuses on cell proliferation and molecular pathways, lacking human clinical data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32753274",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N>320,000) using a nationwide database",
        "Clear clinical outcome (overall cancer incidence)",
        "Robust statistical methodology (multivariate Cox regression, HRs, 95% CIs) reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32950701",
      "is_good_candidate": true,
      "reasons": [
        "Very large population-based nationwide cohort study (N>732,000)",
        "Employs time-dependent Cox analysis to reduce bias",
        "Clear clinical outcomes (lung cancer risk and mortality) with dose-response reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34725457",
      "is_good_candidate": false,
      "reasons": [
        "In vitro study using MDA-MB-231 breast cancer cell lines",
        "Focuses on metabolic profiling (mechanistic), lacking human clinical data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "20304770",
      "is_good_candidate": false,
      "reasons": [
        "Animal study (Fischer-344 rats)",
        "Lacks human subjects and clinical outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36581893",
      "is_good_candidate": true,
      "reasons": [
        "Pooled analysis of data from two registered randomized placebo-controlled trials (RCTs)",
        "Clear population (breast cancer survivors) and defined intervention (metformin vs placebo)",
        "Robust statistical methods used, providing quantitative data."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "29465545",
      "is_good_candidate": true,
      "reasons": [
        "Large-scale, prospective, multicenter cohort study",
        "Clear clinical outcome (cancer incidence) with long follow-up (mean 5.8 years)",
        "Robust statistical reporting (HR 0.513, 95% CI 0.318-0.826) and adjustment for confounders."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32462322",
      "is_good_candidate": true,
      "reasons": [
        "Very large retrospective cohort study (N>347,000) using national database",
        "Clear outcome focused on specific cancer incidence (stomach cancer)",
        "Appropriate statistical methodology (Cox proportional hazards regression, HRs, CIs)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25303400",
      "is_good_candidate": true,
      "reasons": [
        "Extremely large historical cohort study (N>1.4 million)",
        "Uses time-dependent variable approach and reports clear dose-response analysis",
        "Provides highly relevant quantitative data on thyroid cancer risk (HR, CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "19487376",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort study (N=2,529 total) investigating a specific, critical therapeutic outcome (pathologic complete response, pCR)",
        "Uses multivariate logistic regression to compare well-defined clinical subgroups (diabetic metformin users vs non-users)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "20204498",
      "is_good_candidate": false,
      "reasons": [
        "Animal study (Balb/c mice model)",
        "Lacks human subjects and clinical outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34629300",
      "is_good_candidate": true,
      "reasons": [
        "Prospective, multicentric, randomized Phase II study (RCT)",
        "Clear intervention (DOCE + MET vs DOCE + Placebo) and measurable clinical endpoints (PSA response, PFS, OS).",
        "Gold standard methodology for intervention evaluation."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "21696791",
      "is_good_candidate": true,
      "reasons": [
        "Large historical cohort study (N>36,000)",
        "Investigates association between specific glucose-lowering agents and incident cancer",
        "Statistical analysis includes multivariate adjustment and HRs/CIs."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "20551014",
      "is_good_candidate": true,
      "reasons": [
        "Nested case-control study design, providing high-quality observational data on cancer incidence",
        "Uses appropriate matching and multivariate analysis (OR, CI), controlling for metformin exposure."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "19221498",
      "is_good_candidate": false,
      "reasons": [
        "In vitro study using breast cancer cell lines",
        "Results are preclinical/mechanistic, lacking human clinical outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30895533",
      "is_good_candidate": true,
      "reasons": [
        "Large longitudinal observational cohort study using a nationwide database",
        "Employs robust nested case-control and cohort analysis methods",
        "Clear clinical outcome (breast cancer incidence) and statistical reporting (HR, CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35422875",
      "is_good_candidate": false,
      "reasons": [
        "In vitro study using nasopharyngeal carcinoma cells",
        "Focuses on cell activity and apoptosis assays, lacking human clinical outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27220959",
      "is_good_candidate": false,
      "reasons": [
        "Review, commentary, and opinion piece",
        "Does not present original quantitative clinical data suitable for meta-analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "24509842",
      "is_good_candidate": true,
      "reasons": [
        "Very large historical cohort study (N>940,000)",
        "Uses time-dependent variables and reports clear dose-response relationship for bladder cancer risk",
        "Robust statistical reporting (HR, CI, P-trend)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "24816805",
      "is_good_candidate": true,
      "reasons": [
        "Very large historical cohort study (N>476,000 female patients)",
        "Uses time-dependent variables and reports clear dose-response relationship for breast cancer risk",
        "Robust statistical reporting (HR, CI, P-trend)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27304493",
      "is_good_candidate": false,
      "reasons": [
        "Commentary/brief review summarizing findings from other publications",
        "Does not contain original quantitative data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29447929",
      "is_good_candidate": false,
      "reasons": [
        "Theoretical/hypothetical paper proposing a concept and future trial",
        "Does not contain primary quantitative data from a completed clinical study."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37354679",
      "is_good_candidate": false,
      "reasons": [
        "Congress report/Editorial/Opinion piece",
        "Lacks structured quantitative methodology and relies on speculative associations and small clinical observations."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "31293823",
      "is_good_candidate": false,
      "reasons": [
        "Review article summarizing existing literature",
        "Does not present original primary quantitative data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "28981404",
      "is_good_candidate": true,
      "reasons": [
        "Large longitudinal observational cohort study using robust statistical methods (propensity score matching, competing risk regression)",
        "Reports specific quantitative associations between metformin use and lower risks of cancer incidence and mortality (aSHR, CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "16189280",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical/mechanistic study using microarray profiling and gene expression biomarkers",
        "Outcomes are surrogate markers, not human clinical endpoints (cancer incidence, survival)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "37522769",
      "is_good_candidate": false,
      "reasons": [
        "Theoretical scientific thesis based on a very small case series (N=4 patients)",
        "Lacks robust cohort or randomized trial methodology, statistical power, and generalizability."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "28169131",
      "is_good_candidate": true,
      "reasons": [
        "Observational study using rigorous methodology (propensity score matching, time-dependent Cox model)",
        "Provides high-quality quantitative data on cancer patients and antidiabetic drug safety/risk of metastases."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "28190681",
      "is_good_candidate": true,
      "reasons": [
        "Large longitudinal cohort study (N>41,000) with long follow-up (8.8 years)",
        "Uses advanced latent class modeling to assess metformin effects on multiple clinical outcomes, including cancer risk."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32660613",
      "is_good_candidate": true,
      "reasons": [
        "Prospective cohort study (registered trial) with defined intervention (metformin) and follow-up (1 year)",
        "Provides quantitative data on important mechanistic/surrogate outcomes (mtDNA-CN, testosterone) in a well-defined population (PCOS)."
      ],
      "confidence_score": 0.85
    },
    {
      "pmid": "29728105",
      "is_good_candidate": false,
      "reasons": [
        "Small sample size (N=117 total, N=9 metformin users) for the primary exposure comparison",
        "The primary outcome (L'Hermitte's sign) is a specific toxicity, not a general efficacy or cancer incidence outcome suitable for meta-analysis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "24878085",
      "is_good_candidate": true,
      "reasons": [
        "Prospective, randomized, experimental study (clinical trial structure)",
        "Clear intervention (Metformin + Chemo) and measurable clinical endpoints (relapse, survival).",
        "Provides quantitative data suitable for focused meta-analysis on specific cancer treatment."
      ],
      "confidence_score": 0.85
    },
    {
      "pmid": "32456015",
      "is_good_candidate": true,
      "reasons": [
        "Large nationwide population-based longitudinal study with rigorous matching and adjustment",
        "Quantitatively assesses the effect of metformin use in a subgroup (PCOS) on a major clinical outcome (GH-PE risk)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "15053248",
      "is_good_candidate": false,
      "reasons": [
        "Case report/small case series (N=2 women)",
        "Sample size is insufficient for quantitative meta-analysis inclusion."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34983571",
      "is_good_candidate": true,
      "reasons": [
        "Longitudinal cohort study (N=108) with defined intervention and follow-up (12 months)",
        "Reports quantitative efficacy data using surrogate markers (BMI, FAI) and multivariate analysis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "25424411",
      "is_good_candidate": true,
      "reasons": [
        "Large case-control study using nationwide US insurance databases",
        "Addresses a clear clinical outcome (CRC prevention) and uses appropriate methodology (conditional logistic regression, AOR, CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "31815634",
      "is_good_candidate": true,
      "reasons": [
        "Large cohort study (N=4,030) using linked health records",
        "Addresses critical cardiovascular outcomes and mortality using adjusted Cox regression analysis (HR, CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32544018",
      "is_good_candidate": false,
      "reasons": [
        "Small sample size (N=28) retrospective pilot study",
        "Outcomes are surrogate metabolic/vascular markers rather than hard clinical endpoints."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "12192894",
      "is_good_candidate": true,
      "reasons": [
        "Prospective cohort study with defined intervention and follow-up (6 months)",
        "Provides quantitative data on multiple clinical and endocrine endpoints relevant for PCOS meta-analyses (menstrual cyclicity, BMI, androgens)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "20500100",
      "is_good_candidate": false,
      "reasons": [
        "Small sample size (N=36) and complex, combined polytherapy intervention",
        "Difficult to isolate the independent effect of metformin; outcomes are mainly surrogate markers."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "24529918",
      "is_good_candidate": false,
      "reasons": [
        "Primary objective is the effect of rosiglitazone withdrawal, not metformin efficacy or safety",
        "Metformin is a confounder/background therapy, not the primary exposure of interest."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "32581289",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N>20,000) using propensity score matching",
        "Includes lung cancer incidence as a measured clinical outcome (HR, CI) suitable for meta-analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38888178",
      "is_good_candidate": false,
      "reasons": [
        "Cross-sectional study focusing on disease association (PCOS and MetS prevalence) based on inflammation and menopausal status",
        "Does not evaluate the effect of metformin intervention on clinical outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "15624270",
      "is_good_candidate": false,
      "reasons": [
        "Very small longitudinal prospective study (N=21)",
        "Sample size and short follow-up (8 weeks) limit robustness for quantitative meta-analysis inclusion."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "23194004",
      "is_good_candidate": false,
      "reasons": [
        "Very small longitudinal study (N=20 intervention group) with short duration (8 weeks)",
        "Outcomes are primarily biomarkers (AMH) rather than hard clinical endpoints; sample size is inadequate."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "34277970",
      "is_good_candidate": false,
      "reasons": [
        "Study focuses on health policy outcomes (drug utilization and adherence patterns based on insurance)",
        "Metformin is a baseline drug, not the primary intervention or clinical outcome being evaluated."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "33207942",
      "is_good_candidate": true,
      "reasons": [
        "Large cohort study (N=7,803 BC patients) using linked national databases (SEER-Medicare)",
        "Assesses a relevant clinical outcome (cancer stage at diagnosis) comparing metformin users to other ADM users (OR, CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "16716324",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective study analyzing a major clinical endpoint in PCOS (menstrual cyclicity normalization)",
        "Provides quantitative response rates based on duration of metformin treatment."
      ],
      "confidence_score": 0.85
    },
    {
      "pmid": "14998944",
      "is_good_candidate": true,
      "reasons": [
        "Prospective observational study with longitudinal follow-up through pregnancy (N=42 pregnancies)",
        "Focuses on critical clinical outcomes (Gestational Diabetes development) and physiological metrics (IR, weight gain) in a high-risk population (PCOS)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29325133",
      "is_good_candidate": false,
      "reasons": [
        "Study utilizes a prospective cohort design, which is observational and non-randomized.",
        "Lacks a concurrent control group (e.g., placebo or alternative treatment) necessary for high-quality intervention meta-analysis."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "19375579",
      "is_good_candidate": false,
      "reasons": [
        "The study design is primarily cross-sectional and longitudinal observational.",
        "Lacks the methodology of a randomized controlled trial (RCT) necessary for high-quality efficacy meta-analysis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "21359582",
      "is_good_candidate": true,
      "reasons": [
        "This is a post hoc analysis derived from a major randomized controlled trial (DIGAMI 2).",
        "Provides long-term clinical outcome data (mortality, morbidity) with clear statistical measures (HR, OR, 95% CI).",
        "Highly relevant clinical population (patients with MI and Type 2 diabetes)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "37265016",
      "is_good_candidate": true,
      "reasons": [
        "Clear Randomized Controlled Trial (RCT) methodology with defined intervention groups (Metformin monotherapy vs. Combination therapy).",
        "Well-defined study population (overweight/obese women with PCOS).",
        "Measurable outcomes assessed (menstrual cycle, HOMA-IR, hormonal parameters)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39353946",
      "is_good_candidate": false,
      "reasons": [
        "The study is based on preclinical findings using mouse PCOS models.",
        "Excluded due to criterion: Animal studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27808588",
      "is_good_candidate": true,
      "reasons": [
        "Clear randomized study methodology comparing two active interventions (metformin vs. myo-inositol).",
        "Well-defined population (PCOS women with IR/hyperinsulinemia).",
        "Measurable clinical and metabolic outcomes (BMI, HOMA-IR, menstrual cycle, hirsutism)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36755918",
      "is_good_candidate": false,
      "reasons": [
        "The study uses a PCOS mouse model and focuses on molecular mechanisms (ferroptosis, signaling pathways).",
        "Excluded due to criterion: Animal studies and mechanistic focus."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34907435",
      "is_good_candidate": true,
      "reasons": [
        "High quality three-armed Randomized Controlled Trial (RCT) design (Acupuncture vs. Metformin vs. Sham).",
        "Large, adequate sample size (n=342).",
        "Clear primary outcome (HOMA-IR change) and detailed statistical reporting (CI, p-values)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30842661",
      "is_good_candidate": false,
      "reasons": [
        "The study focuses on molecular and mechanistic findings using cell lines and patient-derived tumor xenografts.",
        "Excluded due to criterion: Animal studies and in vitro studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32286137",
      "is_good_candidate": false,
      "reasons": [
        "The study focuses on molecular mechanisms (AMPK/SIRT1 pathway) and uses cancer cell lines (in vitro).",
        "Excluded due to criterion: In vitro studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36060969",
      "is_good_candidate": true,
      "reasons": [
        "Clear Randomized Controlled Trial (RCT) methodology (n=60) comparing Metformin monotherapy versus combination therapy (Metformin + Liraglutide).",
        "Well-defined clinical outcomes related to gonadal and metabolic profiles.",
        "Statistical analysis comparing outcomes between groups is provided."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37573301",
      "is_good_candidate": false,
      "reasons": [
        "The study focuses on signaling pathways (STAT3/LKB1/mTORC1/CREB) using mouse models and xenografts.",
        "Excluded due to criterion: Animal studies and mechanistic focus."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32243780",
      "is_good_candidate": false,
      "reasons": [
        "The research is a mechanistic study using mouse models and organoids.",
        "Excluded due to criterion: Animal studies and mechanistic focus."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38880216",
      "is_good_candidate": false,
      "reasons": [
        "The study uses an obese PCOS mouse model to examine drug effects.",
        "Excluded due to criterion: Animal studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40041289",
      "is_good_candidate": false,
      "reasons": [
        "The study investigates mechanisms in a rat model of PCOS.",
        "Excluded due to criterion: Animal studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39415242",
      "is_good_candidate": true,
      "reasons": [
        "Includes a pragmatic, randomized, controlled clinical study (n=230 women) with clear intervention (NAC) and control groups.",
        "Primary clinical outcomes (ovulation induction efficacy, pregnancy rates) are measurable and statistically compared."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39748269",
      "is_good_candidate": true,
      "reasons": [
        "Clear Randomized Controlled Trial (RCT) methodology comparing two active drugs (Hydroxychloroquine vs. Metformin).",
        "Defined clinical endpoints (metabolism, body fat, hormones) and statistical comparisons are reported.",
        "Clinical trial registration is provided."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39357046",
      "is_good_candidate": true,
      "reasons": [
        "Clear Randomized Controlled Trial (RCT) methodology (n=80) comparing a digital intervention versus Metformin.",
        "Well-defined population (PCOS women with IR) and measurable primary outcome (HOMA-IR change).",
        "Detailed statistical reporting (95% CI, p-values) and clinical trial registration."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30111296",
      "is_good_candidate": false,
      "reasons": [
        "The study is primarily an in vitro investigation focused on developing nano-carriers and analyzing mechanistic metabolic pathways in cancer cells.",
        "Excluded due to criterion: In vitro mechanistic study."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30022161",
      "is_good_candidate": false,
      "reasons": [
        "The study focuses on molecular mechanisms (TET2 phosphorylation, AMPK, 5hmC) using in vitro and in vivo models.",
        "Excluded due to criterion: Animal studies and in vitro studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27746051",
      "is_good_candidate": false,
      "reasons": [
        "The study is a mechanistic metabolomics analysis using patient biopsies and animal tumors, focusing on biomarker discovery rather than clinical efficacy.",
        "Design is non-RCT and geared toward basic science insights."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "39847053",
      "is_good_candidate": true,
      "reasons": [
        "Clear prospective clinical trial design (implied RCT, 'divided equally') comparing two active treatments (MI/DCI vs. Metformin).",
        "Well-defined PCOS population and measurable clinical endpoints (HOMA-IR, SHBG, ovulation).",
        "Clinical trial registration is provided."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "37204669",
      "is_good_candidate": false,
      "reasons": [
        "The study is an animal investigation using mice with breast cancer to analyze radioproteomics.",
        "Excluded due to criterion: Animal studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "24533710",
      "is_good_candidate": false,
      "reasons": [
        "The study is an observational genetic association study (pharmacogenetics) and does not assess intervention efficacy directly.",
        "The methodology is cohort-based genotyping prior to treatment, not an RCT."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "19502420",
      "is_good_candidate": false,
      "reasons": [
        "The study is primarily mechanistic and observational, combining cross-sectional, in vivo infusion, ex vivo, and non-randomized longitudinal intervention data (n=21).",
        "Lacks the methodology of a robust RCT for intervention efficacy."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "24480191",
      "is_good_candidate": false,
      "reasons": [
        "The study is an in vitro investigation using cancer cells to explore metabolic reprogramming.",
        "Excluded due to criterion: In vitro studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38811809",
      "is_good_candidate": false,
      "reasons": [
        "The research methodology involves bioinformatics analysis combined with in vitro experiments (A549 cells).",
        "Excluded due to criterion: In vitro and mechanistic study."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "20557275",
      "is_good_candidate": false,
      "reasons": [
        "This is a review article/commentary summarizing existing epidemiological, in vitro, and in vivo evidence.",
        "Excluded due to criterion: Editorial comments, letters, or opinions."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "24913417",
      "is_good_candidate": false,
      "reasons": [
        "This is a summary/review article presenting the 'pros' of metformin use in PCOS.",
        "Excluded due to criterion: Editorial comments or opinions."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30244975",
      "is_good_candidate": false,
      "reasons": [
        "The study is a pharmacodynamic analysis focused on metabolic biomarkers (metabolomics, transcriptomics) in breast cancer biopsies, not a standard clinical efficacy RCT.",
        "Focus is highly mechanistic and on adaptation pathways."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "36147577",
      "is_good_candidate": true,
      "reasons": [
        "Clear Randomized Controlled Trial (RCT) methodology comparing combination therapy (CANA/MET) vs. monotherapy (MET).",
        "Well-defined population (overweight/obese non-diabetic PCOS women).",
        "Reports statistical comparisons of gonadal and metabolic profiles, and adverse events.",
        "Clinical trial registration is provided."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "24682417",
      "is_good_candidate": false,
      "reasons": [
        "This is a review article summarizing molecular pathways and clinical trials.",
        "Excluded due to criterion: Editorial comments or opinions (review article)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38956672",
      "is_good_candidate": false,
      "reasons": [
        "The study is a small, preliminary case-control investigation (n=5 patients) focusing on mechanistic changes (microbial EVs).",
        "Fails the criterion for adequate sample size and general methodological rigor for intervention MA."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "28089566",
      "is_good_candidate": false,
      "reasons": [
        "The research is a mechanistic study using mouse liver tissue and primary hepatocytes (in vitro/animal focus).",
        "Excluded due to criterion: Animal studies and in vitro studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30860580",
      "is_good_candidate": false,
      "reasons": [
        "The study is an in vitro/ex vivo investigation using primary cell cultures and cell lines from PitNETs.",
        "Excluded due to criterion: In vitro studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37354673",
      "is_good_candidate": false,
      "reasons": [
        "The study is a longitudinal observational intervention (PCOS patients taking Metformin) without randomization or a formal control group.",
        "Design is weaker than a controlled trial for efficacy meta-analysis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "38735598",
      "is_good_candidate": false,
      "reasons": [
        "The study uses an induced PCOS rat model to compare interventions.",
        "Excluded due to criterion: Animal studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37347114",
      "is_good_candidate": true,
      "reasons": [
        "Clear randomized trial design comparing combination therapy versus monotherapy (MET vs. MET+Beinaglutide).",
        "Despite being a 'pilot' study, it reports quantitative clinical outcomes (weight loss, HOMA-IR, TT) with statistical measures.",
        "Clinical trial registration is provided."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "36932437",
      "is_good_candidate": false,
      "reasons": [
        "The study is a mechanistic in vitro investigation using human granulosa cells.",
        "Focuses on molecular signaling pathways (INSR, PI(3)K, PPAR), not clinical efficacy."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36803912",
      "is_good_candidate": false,
      "reasons": [
        "This is a bibliometric study (analysis of publication trends/keywords).",
        "Does not provide primary data from a clinical trial or systematic review."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "24676011",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is missing.",
        "The title suggests an editorial, debate, or opinion piece, not an article providing primary data."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "30858485",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is missing.",
        "The title suggests a review or mechanistic commentary.",
        "Lack of methodological clarity."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "32209321",
      "is_good_candidate": false,
      "reasons": [
        "The study is an in vitro investigation using neuronal cells focusing on molecular pathways (PP5/AMPK-JNK).",
        "Excluded due to criterion: In vitro studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32720198",
      "is_good_candidate": true,
      "reasons": [
        "Clear three-group Randomized Controlled Trial (RCT) methodology (Sitagliptin vs. Metformin vs. Placebo).",
        "Well-defined population (PCOS patients undergoing ICSI) and measurable outcomes (oocyte/embryo quality, pregnancy rates).",
        "Clinical trial registration is provided."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36843612",
      "is_good_candidate": false,
      "reasons": [
        "This is a retrospective analysis using non-randomized data (metformin use based on clinical criteria).",
        "Retrospective design introduces high risk of selection bias/confounding, making it unsuitable for meta-analysis focusing on intervention efficacy derived from RCTs."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "28114390",
      "is_good_candidate": false,
      "reasons": [
        "The study focuses on molecular mechanisms (STAT3 activation) using in vitro cell lines and a xenograft tumor model.",
        "Excluded due to criterion: Animal studies and in vitro studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "31137785",
      "is_good_candidate": false,
      "reasons": [
        "The study is an in vitro investigation using human prostate cancer cells to assess molecular sensitization.",
        "Excluded due to criterion: In vitro mechanistic study."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "31082618",
      "is_good_candidate": false,
      "reasons": [
        "The study is a mechanistic investigation focused on phosphorylation pathways (AMPK/PI3K/Akt) in colorectal cancer cells (in vitro).",
        "Excluded due to criterion: In vitro studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34234193",
      "is_good_candidate": false,
      "reasons": [
        "The research utilizes in vitro cancer cell lines and xenograft nude mice models.",
        "Excluded due to criterion: Animal studies and in vitro studies only."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35821253",
      "is_good_candidate": false,
      "reasons": [
        "The study is highly mechanistic, focusing on T-cell metabolism and tumor immunosurveillance using in vitro, in vivo, and patient data.",
        "Not a controlled clinical efficacy trial."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "30866414",
      "is_good_candidate": false,
      "reasons": [
        "In vitro study using cancer cell lines.",
        "Focuses purely on molecular mechanism (integrin 1, anoikis), lacking human clinical efficacy data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34726324",
      "is_good_candidate": true,
      "reasons": [
        "Randomized controlled trial (RCT) comparing two active interventions (Canagliflozin vs Metformin).",
        "Clear primary outcome (HOMA-IR) reported with effect size and 95% confidence interval.",
        "Well-defined clinical population (PCOS with IR)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "17327307",
      "is_good_candidate": true,
      "reasons": [
        "Controlled clinical trial design with randomization.",
        "Clear intervention arms (Metformin vs OCP combinations) in a defined population (PCOS, overweight).",
        "Measurable primary outcomes (insulin resistance, arterial stiffness) reported with statistical analysis."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "30468782",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical, mechanistic study utilizing mouse embryonic fibroblasts (MEF) and human cell lines.",
        "Focuses on metabolomics and molecular pathways (AMPK-independent effects), not clinical outcomes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37782190",
      "is_good_candidate": false,
      "reasons": [
        "In vitro mechanistic study using murine macrophage and osteoblastic cell lines.",
        "Focuses on molecular pathways (AMPK, mTOR) and osteoclast differentiation, lacks clinical relevance for efficacy meta-analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "21928327",
      "is_good_candidate": false,
      "reasons": [
        "Review article or editorial discussing the potential of a molecular target (AMPK) in malignancies.",
        "Does not present original quantifiable data from a primary study."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39155689",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study utilizing an animal model (PCOS rats).",
        "Focuses on molecular mechanisms (AMPK/AKT/mTOR pathway and autophagy) in animal tissue."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "23577418",
      "is_good_candidate": false,
      "reasons": [
        "Review article summarizing treatment strategies for PCOS.",
        "Does not provide original data from a structured interventional or observational study."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37399981",
      "is_good_candidate": false,
      "reasons": [
        "In vitro mechanistic study using glioblastoma cell lines.",
        "Focuses on combination therapy mechanisms (ROS-AMPK-mTOR axis) in cell culture models."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29705631",
      "is_good_candidate": false,
      "reasons": [
        "In vitro mechanistic study using HepG2 cell lines and metabolomics.",
        "Investigates metabolic changes and pathway activation (AMPK/mTOR) in a cell model."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37681914",
      "is_good_candidate": false,
      "reasons": [
        "Review article focusing on the molecular mechanism of metformin (Wnt signaling pathway).",
        "Does not present original quantifiable clinical data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36232780",
      "is_good_candidate": false,
      "reasons": [
        "Small pilot/exploratory study (N=26) on healthy subjects.",
        "Focuses on lipidomic biomarkers and pharmacokinetic changes after a single dose, not clinical efficacy in a disease state."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "33861440",
      "is_good_candidate": true,
      "reasons": [
        "Randomized controlled trial (RCT) comparing Metformin plus Curcumin versus Metformin alone.",
        "Well-defined population (PCOS women) and measurable clinical/biochemical outcomes (HOMA-IR, lipids, testosterone).",
        "Reports statistical differences and effect sizes."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38831454",
      "is_good_candidate": false,
      "reasons": [
        "Mechanistic study using cell viability assays and tumor xenograft models (animal model).",
        "Focuses on epigenetic mechanisms (H3K9 acetylation) of metformin action."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "23958241",
      "is_good_candidate": true,
      "reasons": [
        "Controlled clinical intervention study, although sequential, with defined groups (PCOS, NC subjects).",
        "Evaluates effects of anti-diabetic therapies (Pioglitazone, Metformin) on insulin action (clamp) and inflammatory markers in skeletal muscle.",
        "Provides quantifiable human physiological data."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "16764619",
      "is_good_candidate": true,
      "reasons": [
        "Randomized clinical study (RCT) design.",
        "Clear comparison groups (LOD alone vs LOD + Metformin) and specific clinical outcomes (ovulation rate, pregnancy rate, insulin resistance).",
        "Reports effect sizes and statistical comparisons (P < 0.05)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30612112",
      "is_good_candidate": false,
      "reasons": [
        "Study protocol describing a future randomized controlled trial (RCT).",
        "Does not present completed results or quantifiable data for analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32276996",
      "is_good_candidate": false,
      "reasons": [
        "Case report (adolescent girl) and general clinical commentary on a specific PCOS subphenotype (HAIR-AN syndrome).",
        "Lacks aggregated, quantifiable data from a structured study."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34743745",
      "is_good_candidate": false,
      "reasons": [
        "Study protocol for a randomized controlled trial (RCT).",
        "Does not present completed results or quantifiable data for analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38126764",
      "is_good_candidate": false,
      "reasons": [
        "Phase I dose-escalation clinical study (N=30 patients).",
        "Primary focus is on safety, tolerability, and MTD determination, not powered for definitive efficacy conclusions."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "25940306",
      "is_good_candidate": false,
      "reasons": [
        "In vitro mechanistic study using human and mouse cancer cell lines.",
        "Focuses on synergy and inhibition of de novo lipogenesis pathways, lacks clinical relevance."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "28770330",
      "is_good_candidate": false,
      "reasons": [
        "Review article discussing the status of metformin therapy in PCOS.",
        "Does not provide original primary data suitable for pooling."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30182764",
      "is_good_candidate": false,
      "reasons": [
        "Explicitly labeled as a 'pilot trial'.",
        "Small sample size (N=44) and potential lack of sufficient statistical power for inclusion in meta-analyses focusing on major efficacy outcomes."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "29659896",
      "is_good_candidate": true,
      "reasons": [
        "Long-term follow-up study of a prior randomized controlled trial (RCT).",
        "Reports robust, quantifiable data (weight gain, BMI, lipids) for long-term metabolic outcomes (7.7 years).",
        "Clear comparison based on original RCT allocation (Metformin vs Placebo during pregnancy)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "16817823",
      "is_good_candidate": false,
      "reasons": [
        "Small sample size (N=16).",
        "Non-randomized, single-arm, before-and-after intervention study.",
        "Focuses on a surrogate outcome (Coronary Flow Reserve) rather than hard clinical endpoints."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "26794854",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study utilizing cancer cell lines and experimental animal models (xenografts).",
        "Focuses on mechanistic compromise of metabolism (glycolysis, OXPHOS) rather than clinical efficacy."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29334602",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study using cell lines and an orthotopic mice model.",
        "Reports survival data only in animals and mechanistic findings (AMPK, AKT pathway)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32067218",
      "is_good_candidate": true,
      "reasons": [
        "Includes an interventional component where 43 PCOS women were randomized to six months of oral metformin therapy.",
        "Reports quantifiable changes in clinically relevant outcomes (insulin sensitivity via clamp, HOMA-IR, FAI)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "24157941",
      "is_good_candidate": false,
      "reasons": [
        "In vitro mechanistic study using human and mouse cancer cell lines.",
        "Focuses on antagonistic effects via STAT3- and AMPK/LKB1-dependent pathways."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39558974",
      "is_good_candidate": false,
      "reasons": [
        "Study utilizes a non-mammalian model organism (*C. elegans*).",
        "Findings are preclinical and focused on longevity mechanisms (DAF-16/FOXO-independent)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39422716",
      "is_good_candidate": false,
      "reasons": [
        "Pharmacogenetic study relying on an animal model (knockin mice) for in vivo pharmacokinetics and efficacy assessment.",
        "Human component is solely genotyping/prevalence assessment, not a clinical trial of efficacy."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40358794",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical study using an animal model (letrozole-induced PCOS rat model).",
        "Focuses on physiological and molecular outcomes (AMPK/GLUT4) in animals."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25866577",
      "is_good_candidate": false,
      "reasons": [
        "Brief review/narrative summary of clinical pharmacology.",
        "Does not provide original, quantifiable data from a structured study."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34649197",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical research focusing on nanotherapeutic synthesis, delivery mechanism, and in vitro/tumor model testing.",
        "Lacks human clinical efficacy data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27775072",
      "is_good_candidate": false,
      "reasons": [
        "Primarily a molecular mechanistic study (H19/SAHH axis, DNA methylation).",
        "The clinical component (human tissue analysis) is used to validate the molecular mechanism, not to report clinical outcomes from a trial."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39206686",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical drug development study focusing on the mechanism of a novel conjugate in NSCLC cells and animal models.",
        "Lacks human clinical trial data on efficacy or safety."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39111591",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective analysis of a multicenter randomized controlled trial (RCT) dataset (N=114).",
        "Provides quantifiable data on metformin efficacy (HOMA-IR changes) suitable for data pooling or sensitivity analysis."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "25903858",
      "is_good_candidate": false,
      "reasons": [
        "In vitro mechanistic study using prostate cancer cell lines.",
        "Focuses on synergistic antiproliferative effects and molecular pathways (AMPK/mTOR) in culture."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "33609439",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical/mechanistic study focused on mitochondrial respiration and metabolic coupling (asparagine) using mouse cancer models.",
        "Lacks human clinical efficacy data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34006565",
      "is_good_candidate": true,
      "reasons": [
        "Randomized controlled trial (RCT) comparing Metformin, behavioral weight loss, and control (N=121).",
        "Clear intervention, defined outcomes (microbiome composition, SCFAs, fasting insulin), and reported associations suitable for data extraction."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36734151",
      "is_good_candidate": false,
      "reasons": [
        "Non-informative abstract (likely review, editorial, or commentary).",
        "Title suggests a broad, general discussion lacking specific methodological detail or primary data."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "39600254",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study (N>33,000) with robust register linkage.",
        "Clear methodology (Cox regression) for survival analysis (prognosis).",
        "Reports quantifiable effect sizes (HRs and 95% CIs) for clinical outcomes (mortality, recurrence)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35608580",
      "is_good_candidate": true,
      "reasons": [
        "Phase 3 randomized, placebo-controlled, double-blind clinical trial (RCT).",
        "Large sample size (N=3649) and long follow-up (median 96.2 months).",
        "Primary outcome is a hard clinical endpoint (Invasive Disease-Free Survival), reported with HR and 95% CI."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29386513",
      "is_good_candidate": false,
      "reasons": [
        "Mechanistic study using human HCC cell lines and a mouse model.",
        "Focuses on metabolic reprogramming (HK2, oxidative phosphorylation) and drug sensitization mechanisms."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "37667332",
      "is_good_candidate": false,
      "reasons": [
        "Preclinical research focused on establishing an organoid biobank (HRCA-PDOs) and high-throughput drug screening.",
        "Metformin findings derived from ex vivo models, not a clinical trial."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39243730",
      "is_good_candidate": true,
      "reasons": [
        "Exploratory analysis of a Phase III RCT (SPARTAN trial).",
        "Provides quantifiable survival outcomes (OS, MFS) and effect modification data (aHRs, 95% CIs) related to metformin use."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "30848544",
      "is_good_candidate": true,
      "reasons": [
        "Systematic review and meta-regression analysis of cohort studies.",
        "Provides pooled effect estimates (RR and 95% CI) and methodological assessment, suitable for high-level evidence synthesis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "33262518",
      "is_good_candidate": true,
      "reasons": [
        "Large nationwide population-based cohort study (N=22,324).",
        "Uses robust methods (Cox regression, time-dependent analysis) to determine survival (OS, LCSS).",
        "Reports quantifiable risk estimates (HR and 95% CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38637957",
      "is_good_candidate": true,
      "reasons": [
        "Large cohort study (N=2,779) tracking a clinical outcome (HCC onset).",
        "Uses appropriate survival analysis models (subdistribution hazard models) and reports quantifiable risk estimates (aSHR, 95% CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "25041125",
      "is_good_candidate": true,
      "reasons": [
        "Population-based case-control analysis (high-quality observational design).",
        "Quantifiable risk outcome (HNC risk) reported using adjusted Odds Ratios (ORs and 95% CIs)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39690329",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study utilizing Taiwan's National Health Insurance Research Database.",
        "Rigorous methodology employed, including Propensity Score Matching and competing risk models.",
        "Provides clear quantitative results (HR, CI, IRR, p-values) for a clinically relevant outcome (SSNHL risk)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "26630530",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study with high sample size (N > 240,000).",
        "Rigorous statistical analysis using Propensity Score Weighting (IPTW) and Cox regression.",
        "Clear quantitative results (HR, CI, incidence rates) for kidney cancer risk."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "37649039",
      "is_good_candidate": true,
      "reasons": [
        "Nationwide population-based cohort study with large sample size (N=26,190).",
        "Clear outcomes (BC-specific survival) and quantitative results (HR, 95% CI).",
        "Uses appropriate multivariable Cox proportional hazard models."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "28456789",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study with robust sample size (N > 280,000).",
        "Rigorous methodology including matched sample analysis and Inverse Probability of Treatment Weighting (IPTW).",
        "Provides clear dose-dependent quantitative results (HR, 95% CI)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "29788134",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is empty, making assessment of methodology, results, and suitability for meta-analysis impossible."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27861146",
      "is_good_candidate": true,
      "reasons": [
        "Very large population-based cohort study (N > 300,000).",
        "Rigorous statistical methods (IPTW, matched-pair sensitivity analysis).",
        "Provides clear dose-dependent quantitative results (HR, 95% CI) for esophageal cancer risk."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "26067686",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is empty, making assessment of methodology, results, and suitability for meta-analysis impossible."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32196659",
      "is_good_candidate": true,
      "reasons": [
        "Large nationwide cohort study with defined patient population (diabetic CRC patients, N=16,676).",
        "Uses advanced statistical methods (Multivariate Cox regression, stabilized IPTW).",
        "Clear quantitative mortality outcomes (HR, 95% CI)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "27926515",
      "is_good_candidate": false,
      "reasons": [
        "Study primarily relies on preclinical research (in vitro cell studies and in vivo mouse models).",
        "Lacks human clinical efficacy or risk data suitable for a clinical meta-analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "36688306",
      "is_good_candidate": false,
      "reasons": [
        "Study conducted entirely in a murine (animal) model.",
        "Focuses on preclinical mechanistic and metabolic observations."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38312035",
      "is_good_candidate": false,
      "reasons": [
        "Study conducted entirely in a mouse (animal) model.",
        "Focuses on preclinical mechanistic findings via the inflammatory pathway."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32933550",
      "is_good_candidate": false,
      "reasons": [
        "Cross-sectional study design, which is typically insufficient for assessing drug efficacy or long-term risk for clinical MA.",
        "Outcome (mammographic breast density) is an intermediate biomarker, not a definitive clinical endpoint (e.g., incidence or mortality)."
      ],
      "confidence_score": 0.85
    },
    {
      "pmid": "30980539",
      "is_good_candidate": true,
      "reasons": [
        "Pooled analysis of patient data derived from three Phase III randomized controlled trials (RCTs).",
        "Clear primary clinical outcomes (OS, PFS) analyzed using robust methods (multivariate Cox analyses).",
        "Provides quantitative results (HR, 95% CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "33884414",
      "is_good_candidate": true,
      "reasons": [
        "Randomized, 3-parallel-arm controlled clinical trial (RCT) design.",
        "Clear intervention arms and measurable biomarker outcomes (IGF-1, IGF1:IGFBP3 molar ratio).",
        "Quantitative results (mean difference in change, CIs) are provided."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "25122066",
      "is_good_candidate": false,
      "reasons": [
        "Focuses on in vitro cell line studies and in vivo mouse models.",
        "Preclinical research, not a human clinical trial or epidemiological study."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29788487",
      "is_good_candidate": true,
      "reasons": [
        "Randomized controlled trial (RCT) using a 2x2 factorial design.",
        "Adequate sample size (N=333) and high adherence/completion rate.",
        "Provides quantitative results (percent changes, 95% CI) for key prognostic biomarkers."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "25576058",
      "is_good_candidate": false,
      "reasons": [
        "Study conducted entirely in a mouse (animal) tumor transplant model.",
        "Preclinical focus on mechanistic pathway signaling (mTOR, microRNA)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "33516778",
      "is_good_candidate": true,
      "reasons": [
        "Large prospective cohort study (N=44,541) with long follow-up (median 8.6 years).",
        "Clear definition of exposure and outcome (incident breast cancer risk, stratified by ER status).",
        "Uses appropriate Cox models and provides quantitative results (HR, 95% CI)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "36916886",
      "is_good_candidate": true,
      "reasons": [
        "Post-hoc analysis derived from two randomized controlled trials (PregMet and PregMet2).",
        "Large sample size (N=615) and longitudinal data collection.",
        "Provides quantitative immunological outcomes suitable for MA focusing on biomarkers/mechanisms."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "32035002",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based retrospective cohort study (SEER-Medicare, N=12,700).",
        "Uses robust methodology (Cox proportional hazard model with competing risks and propensity score adjustment).",
        "Clear hard clinical endpoints (all-cause mortality, PCa mortality) with HRs and CIs."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "24963109",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is empty, making assessment of methodology, results, and suitability for meta-analysis impossible."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29802690",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort study focusing on clinical survival outcomes (OS, PFS) in a defined cancer population.",
        "Uses appropriate Cox proportional-hazards regression analysis.",
        "Provides quantitative results (HR, 95% CI) for metformin effect."
      ],
      "confidence_score": 0.85
    },
    {
      "pmid": "35902376",
      "is_good_candidate": true,
      "reasons": [
        "Very large cohort study using SEER-Medicare data (N=143,035).",
        "Uses robust epidemiological methods (conditional logistic and Cox models).",
        "Provides clear quantitative risk estimates (OR, HR, 95% CI) for cancer incidence."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "37695982",
      "is_good_candidate": true,
      "reasons": [
        "Secondary analysis of a large Phase III randomized controlled trial (MA.32).",
        "Focuses on hard clinical outcomes (risk of new primary cancers).",
        "Uses competing risks methodology and provides clear quantitative results (HR, 95% CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "26331456",
      "is_good_candidate": true,
      "reasons": [
        "Population-based cohort study with clear clinical outcome (cancer-specific mortality).",
        "Uses time-dependent Cox regression models to address time-related bias.",
        "Provides quantitative results (HR, 95% CI)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "29511039",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based nested case-control design (N=878 cases, 4,364 controls).",
        "Uses robust statistical methodology (conditional logistic regression).",
        "Provides clear quantitative risk estimates (OR, 95% CI)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "32859615",
      "is_good_candidate": true,
      "reasons": [
        "Phase II randomized controlled trial (RCT) using a 2x2 factorial design.",
        "Clear intervention and measured outcomes (inflammation biomarkers).",
        "Uses rigorous statistical modeling and provides quantitative results (CIs)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "27565939",
      "is_good_candidate": true,
      "reasons": [
        "Population-based retrospective cohort study using linked national datasets.",
        "Uses appropriate Cox regression models and provides quantitative survival results (HR, 95% CI).",
        "Focuses on a specific, clinically relevant outcome (survival in mesothelioma)."
      ],
      "confidence_score": 0.85
    },
    {
      "pmid": "35894762",
      "is_good_candidate": true,
      "reasons": [
        "Bi-centric case-control study with defined cases and controls (N=223 cases, 446 controls).",
        "Provides quantitative statistical estimates (OR, 95% CI) for risk factor assessment.",
        "Clear methodology for epidemiological inclusion."
      ],
      "confidence_score": 0.85
    },
    {
      "pmid": "25956271",
      "is_good_candidate": true,
      "reasons": [
        "Population-based cohort study focusing on hard clinical outcomes (mortality, recurrence).",
        "Uses appropriate methodology (multivariable Cox models, competing risks).",
        "Provides quantitative results (HR, 95% CI)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "32369446",
      "is_good_candidate": true,
      "reasons": [
        "Formal, registered Phase II clinical trial (RCT, NCT01579812).",
        "Provides clinical survival outcomes (PFS, OS, 95% CI) in addition to biomarker data.",
        "Clear description of intervention and patient population."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "31324361",
      "is_good_candidate": true,
      "reasons": [
        "Retrospective cohort study focusing on hard clinical endpoint (overall survival) in specific cancer types.",
        "Provides comparative quantitative survival data (years, P-values).",
        "Clear definition of experimental and control groups."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "31025540",
      "is_good_candidate": false,
      "reasons": [
        "Focuses on in vitro cell line studies and in vivo mechanistic models.",
        "Preclinical study investigating molecular mechanisms (ubiquitination, apoptosis), lacking human clinical data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32271517",
      "is_good_candidate": true,
      "reasons": [
        "Large observational study using SEER-Medicare data (N=2,499).",
        "Analyzes hard clinical outcome (Overall Survival).",
        "Uses robust methodology (Cox proportional hazard models) and provides quantitative results (HR, 95% CI)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "33193076",
      "is_good_candidate": true,
      "reasons": [
        "Very large population-based cohort study (N=610,089).",
        "Rigorous methodology utilizing IPTW and propensity scores.",
        "Provides clear quantitative incidence rates and HRs (95% CI) for leukemia risk."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "35610365",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based prospective cohort study (N=107,706).",
        "Uses multivariable Cox regression analyses to determine risk of PC diagnosis.",
        "Provides clear quantitative risk estimates (HR, 95% CI)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "39099229",
      "is_good_candidate": false,
      "reasons": [
        "This is a survey of clinical practice among endocrinologists.",
        "It does not present primary patient outcome data, randomized comparisons, or epidemiological risk factors suitable for a clinical efficacy MA."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35572351",
      "is_good_candidate": true,
      "reasons": [
        "Very large epidemiological study (N=7.23 million) using insurance claims data.",
        "Uses rigorous statistical methods (Propensity Score stratified analyses).",
        "Provides clear quantitative risk estimates (HR, 95% CI) for disease risk."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "38690892",
      "is_good_candidate": true,
      "reasons": [
        "Secondary analysis of a Phase III randomized controlled trial (COVID-OUT).",
        "Clear methodology and quantitative results (mean difference, OR, 95% CI).",
        "Focuses on a measurable surrogate outcome (viral load)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "37302406",
      "is_good_candidate": true,
      "reasons": [
        "Primary results of a large Phase III randomized controlled trial (RCT).",
        "Quadruple-blind design ensures high quality evidence.",
        "Focuses on a clear long-term clinical outcome (Long COVID incidence) with quantitative results (HR, 95% CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "38154770",
      "is_good_candidate": true,
      "reasons": [
        "Secondary analysis of a large, randomized controlled trial (PPCOS I study).",
        "Provides clear quantitative results (Odds Ratio, 95% CI) based on high-quality trial data.",
        "Clear methodology for assessing prognostic factors."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "39461199",
      "is_good_candidate": true,
      "reasons": [
        "Randomized, double-blind, placebo-controlled factorial trial.",
        "Adequate sample size (N=200) and clear, measurable metabolic and hormonal outcomes.",
        "Provides quantitative results for synergistic effects."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "34590929",
      "is_good_candidate": true,
      "reasons": [
        "Double-blinded randomized controlled trial (RCT) design.",
        "Focuses on key clinical endpoints in fertility treatment (OHSS incidence, pregnancy rates).",
        "Provides detailed quantitative results and comparison statistics."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "38403687",
      "is_good_candidate": true,
      "reasons": [
        "Clinical trial structure comparing metformin vs placebo for FAP treatment.",
        "Measures clinically relevant efficacy outcomes (polyp number and load).",
        "Provides statistical significance results (P < 0.05)."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "32416251",
      "is_good_candidate": false,
      "reasons": [
        "This analysis is a safety and adverse event management report for a different primary drug (alpelisib) in a Phase III trial.",
        "Metformin is studied only as a concomitant therapy for managing side effects, not as the primary intervention for cancer outcomes or risk."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40675492",
      "is_good_candidate": true,
      "reasons": [
        "Large prospective cohort analysis derived from the long-term follow-up of the DPP RCT (N=3000).",
        "Uses Cox proportional hazard models to estimate cancer risk (HR, 95% CI).",
        "High quality longitudinal observational data."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "38758294",
      "is_good_candidate": true,
      "reasons": [
        "Secondary analysis using data from the large randomized Diabetes Prevention Program (DPP) trial.",
        "Uses rigorous statistical models (General linear models, Cox regression) on patient data.",
        "Provides quantitative results regarding genetic predictors of T2D incidence."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "37769677",
      "is_good_candidate": false,
      "reasons": [
        "This specific post-hoc analysis explicitly excludes participants randomized to the metformin intervention arm.",
        "The findings investigate weight loss mechanisms in lifestyle/placebo groups, making it unsuitable for a metformin MA."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40639383",
      "is_good_candidate": true,
      "reasons": [
        "Large-scale Phase III randomized controlled trial (STAMPEDE platform).",
        "Focuses on the hard clinical endpoint of Overall Survival in metastatic prostate cancer.",
        "Provides clear quantitative results (HR, 95% CI) based on intention-to-treat analysis."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "39437217",
      "is_good_candidate": true,
      "reasons": [
        "Randomized, double-blind, placebo-controlled trial.",
        "Clear intervention and measurable biochemical outcome (postoperative hyperglycemia).",
        "Provides quantitative results suitable for pooling in MA of perioperative effects."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "31570268",
      "is_good_candidate": false,
      "reasons": [
        "This is a Phase 1 dose-escalation study (3+3 design).",
        "The primary objective is safety/Maximum Tolerated Dose (MTD), not clinical efficacy.",
        "Very small sample size (N=8 enrolled)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "33653815",
      "is_good_candidate": true,
      "reasons": [
        "Large population-based cohort study (N=6,537).",
        "Clear prognostic outcomes (prostate cancer death, ADT initiation).",
        "Robust statistical analysis (multivariable-adjusted Cox regression) providing HRs and CIs."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "34697033",
      "is_good_candidate": true,
      "reasons": [
        "Long-term follow-up (21 years) of a large, definitive randomized controlled trial (DPP/DPPOS).",
        "Clear, highly relevant primary clinical outcomes (all-cause and cause-specific mortality).",
        "Provides robust effect sizes (HR, 95% CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34383179",
      "is_good_candidate": true,
      "reasons": [
        "Phase II double-blind, randomized, placebo-controlled trial (RCT).",
        "Clear methodology and measurable outcomes (adiposity, breast density).",
        "Adequate sample size (N=151) and statistical reporting (p-values, quantifiable changes)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "36509462",
      "is_good_candidate": false,
      "reasons": [
        "Phase II, open-label, non-randomized study.",
        "Small sample size (N=30 evaluable subjects).",
        "Lack of a comparative control group limits reliability for meta-analysis of efficacy."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "34444833",
      "is_good_candidate": true,
      "reasons": [
        "Randomized controlled trial (SPIRIT) with clear methodology (three-arm parallel trial).",
        "Clear, measurable outcomes (BMI and serum urate changes).",
        "Provides effect sizes and 95% CI for comparative results."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34322775",
      "is_good_candidate": false,
      "reasons": [
        "Phase 1 dose-escalation trial focused on MTD and DLTs (toxicity and safety).",
        "Very small sample size (N=11 total treated).",
        "Trial was stopped early due to unfavorable toxicity profile."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29602978",
      "is_good_candidate": true,
      "reasons": [
        "Randomized controlled trial (RCT) comparing different combination therapies.",
        "Adequate sample size (N=240 allocated).",
        "Clear, measurable outcomes (androgen parameters, body fat percentage) with statistical analysis (p-values, F statistics)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "30514262",
      "is_good_candidate": false,
      "reasons": [
        "Phase II trial designed primarily as a 2x2 factorial *biomarker* study.",
        "The primary endpoint is a surrogate biomarker (NFB IHC expression) in tissue, not a definitive clinical outcome (e.g., recurrence or survival)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "39641916",
      "is_good_candidate": true,
      "reasons": [
        "Large randomized trial (N=1,442 participants, 4 intervention arms).",
        "Clear primary outcome focused on long-term incidence of major noncommunicable diseases (T2D, CVD, cancer).",
        "High quality, robust intervention study design."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32314464",
      "is_good_candidate": true,
      "reasons": [
        "Randomized, controlled trial comparing two treatments (tofogliflozin vs glimepiride) added to dual therapy.",
        "Clear outcomes (HbA1c, body fat percentage, fat mass) and robust statistical comparison (p-values, mean differences).",
        "Clear methodology for comparative efficacy testing."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "24423336",
      "is_good_candidate": true,
      "reasons": [
        "Substudy analysis derived from a randomized, placebo-controlled, double-blind, multicenter study (N=231 pregnancies).",
        "Clear randomized methodology and quantifiable physiological outcomes (PI of uterine artery) correlated with clinical predictions (preeclampsia, GDM).",
        "Provides robust statistical analysis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "31413010",
      "is_good_candidate": true,
      "reasons": [
        "Randomized, double-blind Phase II trial (N=224 patients).",
        "Primary endpoint is a clinical outcome (Progression-Free Survival rate at 1 year).",
        "Provides essential statistical metrics (median PFS, OS, 95% CI, p-values)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32711460",
      "is_good_candidate": false,
      "reasons": [
        "This is a methodological study focusing on linking a clinical trial (CHHiP) with primary care data.",
        "The goal is data supplementation and methodological recommendations, not reporting primary intervention efficacy results for inclusion in a clinical meta-analysis.",
        "Small linked sample size (N=106)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "29482528",
      "is_good_candidate": true,
      "reasons": [
        "Randomized, parallel, open-label study comparing three distinct treatment regimens.",
        "Clear objectives related to glycemic control and $\\beta$-cell function in a specific population (T2DM+PCOS).",
        "Provides clear comparative statistical results (p-values, percentages)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "28917544",
      "is_good_candidate": true,
      "reasons": [
        "Large, multicenter, randomized, pragmatic clinical trial (N=3028 patients).",
        "Primary outcome is a major composite clinical endpoint (cardiovascular events).",
        "High methodological quality with long-term follow-up and robust statistical reporting (HR, 95% CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "31961463",
      "is_good_candidate": true,
      "reasons": [
        "Randomized controlled trial (RCT) with clear intervention arms and patient population (AEH/EEC).",
        "Clear clinical response outcome (cumulative complete response rate).",
        "Provides appropriate effect measures (OR, 95% CI, p-values)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "38868742",
      "is_good_candidate": false,
      "reasons": [
        "This is a post-hoc analysis of existing RCTs.",
        "The focus is on the observational correlation between maternal thyroid function (prognostic factors) and offspring anthropometrics, rather than the primary comparative efficacy of the randomized intervention (metformin vs placebo)."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "25158895",
      "is_good_candidate": false,
      "reasons": [
        "Animal study conducted in TRAMP mice.",
        "Data is not derived from human clinical trials."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "20926533",
      "is_good_candidate": true,
      "reasons": [
        "Randomized, placebo-controlled, double-blind, multicenter study.",
        "Adequate sample size (N=274 pregnancies).",
        "Clear clinical outcomes (preeclampsia, GDM, preterm delivery, composite endpoint) with robust statistical reporting (prevalence, 95% CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27151652",
      "is_good_candidate": false,
      "reasons": [
        "Retrospective review/pooled analysis of data collected from multiple Phase I trials.",
        "Primary focus is on toxicity incidence (hyperglycemia) and predictive factors, not comparative clinical efficacy/safety of a standardized intervention."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "17145568",
      "is_good_candidate": false,
      "reasons": [
        "Small sample size (N=36) in a prospective assessment/pilot intervention design.",
        "Treatment groups are defined by underlying condition (PCOS, hyperinsulinemia) and tolerance, lacking strict randomization or a true placebo control arm for comparative efficacy.",
        "Methodology is weak for robust meta-analysis."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "26681720",
      "is_good_candidate": true,
      "reasons": [
        "Long-term post-trial follow-up of the definitive ORIGIN RCT.",
        "Focuses on legacy effects and major clinical outcomes (MI, stroke, CV death, cancer).",
        "Provides high-quality survival data (HR, 95% CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "40374694",
      "is_good_candidate": false,
      "reasons": [
        "Phase II trial focused on biomarker endpoints (transcriptomic and metabolomic profiles) in tissue.",
        "Lack of definitive clinical outcomes (e.g., recurrence or survival) suitable for clinical efficacy meta-analysis."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "40711960",
      "is_good_candidate": true,
      "reasons": [
        "Phase 3, multicenter, double-blind, randomized controlled trial.",
        "Primary objective is a clear clinical prevention outcome (Metabolic Syndrome risk).",
        "Provides quantified changes in metabolic markers (weight, HbA1c, waist circumference) and statistical data, despite early closure."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "33661912",
      "is_good_candidate": true,
      "reasons": [
        "Large retrospective cohort study (N=857 total patients) providing real-world evidence.",
        "Clear clinical outcomes (Overall Survival and Recurrence-Free Survival).",
        "Uses robust multivariate analysis to calculate independent predictors (suitable for meta-analysis of observational studies)."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "20684955",
      "is_good_candidate": true,
      "reasons": [
        "Prospective randomized study comparing two active treatments and a no-treatment arm.",
        "Clear physiological surrogate outcome (flow-mediated dilation) relevant to cardiovascular risk.",
        "Provides quantifiable measures and p-values for comparison."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "30910544",
      "is_good_candidate": false,
      "reasons": [
        "Secondary analysis of an existing RCT, focusing on the prognostic correlation of baseline metabolic syndrome status.",
        "Does not test the efficacy of a new randomized intervention, but examines observational risk factors.",
        "Metformin use is a covariate, not the primary intervention being compared for efficacy."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "29490031",
      "is_good_candidate": true,
      "reasons": [
        "Long-term follow-up study (4 years) derived from two previous RCTs.",
        "Focuses on a major clinical safety outcome in offspring (BMI z score, overweight/obesity prevalence).",
        "Provides robust statistical results (OR, 95% CI, p-values)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "19073504",
      "is_good_candidate": false,
      "reasons": [
        "Small sample size (N=32, 22 completed) in an intervention cohort study.",
        "Lacks a concurrent randomized control/placebo group.",
        "Primary outcome is a surrogate biochemical marker (insulin levels), characteristic of a pilot feasibility study."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "19522426",
      "is_good_candidate": false,
      "reasons": [
        "Randomized structure, but very small sample size (N=32 total, 16 per group).",
        "A pilot study lacking sufficient power, as noted by the authors (non-statistically significant difference in primary outcome)."
      ],
      "confidence_score": 0.85
    },
    {
      "pmid": "26706833",
      "is_good_candidate": false,
      "reasons": [
        "Substudy/retrospective analysis of a larger RCT focusing on prognostic biomarkers (IGF1R expression).",
        "Metformin status was likely observational/non-randomized in this cohort.",
        "Focus is correlational and retrospective, not primary comparative efficacy of a randomized intervention."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "32212089",
      "is_good_candidate": true,
      "reasons": [
        "Prospective, randomized study comparing combination therapy to monotherapy (N=80 patients).",
        "Clear clinical endpoints (response to treatment, time to disease progression, overall survival).",
        "Provides statistical data for survival comparison."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "37131014",
      "is_good_candidate": true,
      "reasons": [
        "Randomized controlled trial (RCT) comparing chemotherapy + metformin vs. chemotherapy alone (N=70 non-diabetic patients).",
        "Focuses on clinically relevant toxicity outcomes (neuropathy, mucositis, cardiac function).",
        "Provides quantified comparative results and p-values."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35538143",
      "is_good_candidate": true,
      "reasons": [
        "Open-label randomized controlled trial (N=80 patients).",
        "Primary outcomes are definitive clinical response measures in cancer (ORR, cCr, pCR, BCR).",
        "Clear comparative structure and reported efficacy signals."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "30563932",
      "is_good_candidate": false,
      "reasons": [
        "Randomized, double-blind trial, but defined as a presurgical 'window study'.",
        "Primary outcome is a surrogate biomarker (Ki-67 proliferation marker), not long-term clinical recurrence or survival."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "26067687",
      "is_good_candidate": true,
      "reasons": [
        "Double-blind, randomized, placebo-controlled phase 2 trial (N=121 patients).",
        "Primary endpoint is a definitive clinical outcome (Overall Survival at 6 months).",
        "Provides clear survival metrics (median OS, HR, 95% CI)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "16785142",
      "is_good_candidate": true,
      "reasons": [
        "Randomized study comparing GnRH antagonist protocol with or without metformin (N=40).",
        "Clear reproductive outcomes measured (OHSS incidence, mature oocyte number, cancelled cycles).",
        "Provides comparative mean differences and p-values."
      ],
      "confidence_score": 0.85
    },
    {
      "pmid": "31910850",
      "is_good_candidate": true,
      "reasons": [
        "Prospective, randomized, controlled trial (N=340 patients).",
        "High methodological quality with clear primary and secondary cardiometabolic outcomes.",
        "Provides robust statistical comparison (achievement ratios, 95% CI, p-values)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "34416879",
      "is_good_candidate": true,
      "reasons": [
        "Randomized clinical trial (N=175 patients: 83 treatment, 92 placebo).",
        "Clear primary outcome measure (change in fibroadenoma size/regression).",
        "Provides quantified effect sizes (OR, 95% CI) for comparative efficacy."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "28323503",
      "is_good_candidate": false,
      "reasons": [
        "Small sample size (N=30) in a 12-week randomized study.",
        "Focus is on physiological surrogate markers (insulin resistance, \\beta-cell function), suggesting a preliminary/pilot nature lacking sufficient power or definitive clinical outcomes."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "11163815",
      "is_good_candidate": false,
      "reasons": [
        "Pilot study with a very small sample size (N=19 treated).",
        "Relies on historic controls for comparison of the primary outcome (spontaneous abortion rate), introducing high potential for selection and confounding bias.",
        "Design is not a robust RCT."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "24917306",
      "is_good_candidate": false,
      "reasons": [
        "Preoperative prospective trial (window-of-opportunity study, N=31).",
        "Single-arm design (pre- vs post-intervention comparison).",
        "Primary outcomes are surrogate biomarkers (Ki-67, Topoisomerase II) rather than definitive clinical endpoints."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "33509804",
      "is_good_candidate": true,
      "reasons": [
        "Randomized, double-blind, controlled trial comparing two doses of metformin to placebo.",
        "Primary outcomes are clear clinical/radiological measures (polyp number and size).",
        "Clear RCT methodology providing quantifiable changes."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "31819193",
      "is_good_candidate": false,
      "reasons": [
        "Pre-surgical window study focused on identifying molecular mechanisms (transcriptomic analysis).",
        "Primary endpoint is molecular bioactivity/gene expression changes, not clinical efficacy (recurrence, survival)."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "15136950",
      "is_good_candidate": false,
      "reasons": [
        "Intervention cohort study (N=103) lacking a contemporaneous randomized control/placebo group.",
        "Results are based on observational comparison of baseline vs. post-treatment parameters, highly susceptible to bias."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "39511611",
      "is_good_candidate": false,
      "reasons": [
        "Biomarker substudy/secondary analysis of an existing RCT (OCOG-ALMERA).",
        "Focuses on the prognostic value of a cytokine (GDF15) and its correlation with survival, rather than the primary comparative efficacy of the intervention (metformin)."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "24668327",
      "is_good_candidate": false,
      "reasons": [
        "Abstract is highly incomplete, lacking details on study design (RCT, cohort, etc.), sample size, comparison group, or specific statistical results.",
        "Insufficient methodological information for classification."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35842567",
      "is_good_candidate": false,
      "reasons": [
        "Phase I study specifically designed to assess pharmacokinetic (PK) Drug-Drug Interactions (DDI).",
        "Primary endpoints are related to drug exposure (GMR, AUC) in healthy volunteers, not clinical efficacy or safety of the drugs for their primary indications."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "24605899",
      "is_good_candidate": false,
      "reasons": [
        "Presurgical trial (window study, N=35).",
        "Single-arm intervention compared against historical controls (high risk of bias).",
        "Primary endpoint is a surrogate biomarker (Ki-67 proliferation change), not a long-term clinical outcome."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "24823465",
      "is_good_candidate": true,
      "reasons": [
        "Clear Randomized Controlled Trial (RCT) methodology (12-week prospective, randomized, open-label study).",
        "Well-defined population (obese women with PCOS) and intervention (Metformin vs. Metformin + Roflumilast).",
        "Measurable outcomes (anthropometric measures, BMI, hormonal status, HOMA-IR).",
        "Statistical results reported, including means, SDs, and p-values for primary outcomes.",
        "Adequate sample size (N=36 randomized, 31 completed) for a single trial contribution."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "16169430",
      "is_good_candidate": true,
      "reasons": [
        "Explicitly stated as a prospective randomized trial (RCT).",
        "Clear study population (PCOS patients undergoing IVF/ICSI) and intervention (Metformin).",
        "Clinical outcomes are measurable (IVF/ICSI outcomes).",
        "Methodology is suitable for pooling, despite the abstract being highly concise and lacking detailed statistical reporting (which would typically be present in the full text)."
      ],
      "confidence_score": 0.8
    },
    {
      "pmid": "35872697",
      "is_good_candidate": true,
      "reasons": [
        "Clear Randomized Controlled Trial (RCT) design.",
        "Adequate sample size (N=120) for statistical power.",
        "Well-defined intervention groups (Metformin vs. Metformin + intensive exercise diet therapy).",
        "Multiple measurable clinical and metabolic outcomes (FBG, HbA1c, lipid profile, PFS).",
        "Statistical analysis and significant findings reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35730613",
      "is_good_candidate": false,
      "reasons": [
        "This is a post-hoc analysis leveraging data from an existing RCT (SPIRIT Trial).",
        "The primary focus is an observational/longitudinal analysis investigating associations between biomarkers (circulating and fecal SCFAs) and changes in blood pressure, rather than reporting primary randomized treatment effects.",
        "The study design is associational (correlation analysis) rather than a pure RCT outcome report."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "31140202",
      "is_good_candidate": true,
      "reasons": [
        "Robust methodology: Large-scale RCT using a 2x2 factorial design.",
        "Large sample size (N=333).",
        "Clear population (breast cancer survivors) and interventions (Weight loss vs. Control, Metformin vs. Placebo).",
        "Measurable objective outcomes (changes in cognitive function).",
        "Statistical results reported, including P-values and findings on effect modification."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "21655990",
      "is_good_candidate": false,
      "reasons": [
        "Small sample size (N=47 randomized; pilot cohort N=8).",
        "Window-of-opportunity design primarily focused on biological effects and intermediate biomarkers (Ki67, gene expression) rather than long-term clinical efficacy outcomes (survival, recurrence).",
        "This type of study often represents Phase I/II exploratory data, limiting its contribution to clinical efficacy meta-analyses."
      ],
      "confidence_score": 0.9
    },
    {
      "pmid": "31718828",
      "is_good_candidate": true,
      "reasons": [
        "Clear Prospective Randomized Controlled Trial (RCT) design.",
        "Adequate sample size (N~204 total) across three groups.",
        "Compares multiple active interventions (high-dose Metformin, Rosiglitazone, Combination therapy).",
        "Clear, measurable clinical and metabolic outcomes (weight, BMI, androgen, insulin, lipid levels).",
        "Statistical comparison results between groups are reported."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "35265033",
      "is_good_candidate": true,
      "reasons": [
        "Analysis derived from two large, well-designed randomized, double-blind, placebo-controlled trials (RCTs).",
        "Clear treatment comparison (Metformin vs. Placebo).",
        "Reports treatment effects on measured hormonal and metabolic outcomes (fT4 levels, correlation with weight gain and GDM risk).",
        "The underlying methodology is robust RCT data, making it highly suitable for inclusion."
      ],
      "confidence_score": 0.95
    },
    {
      "pmid": "25740979",
      "is_good_candidate": true,
      "reasons": [
        "Analysis from a large, prospective RCT (NCIC CTG MA.32).",
        "Large sample size (N=492) for this interim analysis.",
        "Clear comparison (Metformin vs. Placebo).",
        "Focuses on measurable metabolic and weight outcomes.",
        "Detailed statistical results reported, including percentages of change and specific p-values."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "27430256",
      "is_good_candidate": false,
      "reasons": [
        "This abstract describes a study protocol for a Phase II RCT.",
        "It does not present completed results, data, or statistical analysis of outcomes.",
        "Meta-analyses require completed studies with reported efficacy data."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "31626727",
      "is_good_candidate": false,
      "reasons": [
        "This is a Phase 1 dose escalation study.",
        "The primary goal is safety and determining the Maximum Tolerated Dose (MTD), not clinical efficacy.",
        "Very small sample size (N=20), insufficient for robust efficacy pooling."
      ],
      "confidence_score": 1.0
    },
    {
      "pmid": "32046384",
      "is_good_candidate": false,
      "reasons": [
        "Pilot study design.",
        "Extremely small sample size (N=8 total: 4 MET, 4 CON).",
        "Focuses on mechanistic/biomarker changes (Ki67, steroid receptors) in tumor tissue, not clinical efficacy.",
        "Insufficient power and size for meaningful meta-analysis inclusion."
      ],
      "confidence_score": 1.0
    }
  ]
}